{
  "MONDO:0004670": [
    {
      "drug_id": "DrugBank::DB00139",
      "drug_name": "DB00139",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00139 and MONDO:0004670 involves EGFR (1956) activation, which triggers TGFB1 (7040) upregulation, leading to PRL (5617) overexpression, ultimately contributing to MONDO:0004670. An alternative pathway also initiates with EGFR (1956) but instead activates ILK (3558), which then upregulates FSCN1 (51311), another potential driver of MONDO:0004670. Both pathways converge on the disease through distinct downstream effectors (PRL or FSCN1) but share EGFR as the common upstream regulator.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 1
    },
    {
      "drug_id": "DrugBank::DB06186",
      "drug_name": "DB06186",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB06186 (a small molecule) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB06186 targets the gene *CYP1A1* (1493), which encodes a cytochrome P450 enzyme involved in xenobiotic metabolism. *CYP1A1* then interacts with *TGFB1* (7040), a cytokine that regulates cell growth and differentiation. *TGFB1* subsequently modulates the expression of *PRL* (5617), a prolactin gene implicated in hormonal signaling. Altered *PRL* activity is directly associated with MONDO:0004670, suggesting that DB06186 may influence the disease through this sequential pathway involving *CYP1A1*, *TGFB1*, and *PRL*. No alternative paths were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 2
    },
    {
      "drug_id": "DrugBank::DB00703",
      "drug_name": "DB00703",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00703 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the **AXIN1** gene (8312), which subsequently modulates **TGFB1** (7040), a key regulator of the **PRKCA** gene (5617) that is directly associated with the disease. Alternatively, DB00703 may also influence the disease through **AXIN1** (8312) by affecting **TP53** (7157), which in turn regulates **PRKCA** (5617). Both pathways converge on **PRKCA**, highlighting its central role in connecting the drug's action to the disease, either through TGFB1-mediated or TP53-mediated regulation.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 3
    },
    {
      "drug_id": "DrugBank::DB01611",
      "drug_name": "DB01611",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01611 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB01611, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRKCA (5617), ultimately influencing the development of MONDO:0004670. Alternatively, DB01611 may also modulate MONDO:0004670 through NFKB1 (4790) by downregulating TP53 (7157), another upstream regulator of PRKCA (5617). Both pathways converge on PRKCA, highlighting its central role in connecting DB01611's effects to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 4
    },
    {
      "drug_id": "DrugBank::DB11094",
      "drug_name": "DB11094",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11094 and MONDO:0004670 involves the gene TGFB1 (7040), which directly connects to PRLR (5617), a key intermediate gene associated with MONDO:0004670. Alternatively, DB11094 may also influence MONDO:0004670 through the IL1B (3558) pathway, where DB11094 first interacts with AR (213), which then activates IL1B, ultimately leading to the disease via the intermediate gene FKBP5 (51311). A third pathway similarly begins with DB11094 acting on AR (213), but instead proceeds through TP53 (7157) to modulate PRLR (5617), again linking to MONDO:0004670. These pathways highlight the central roles of TGFB1, PRLR, IL1B, and AR in mediating the connection between DB11094 and the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 5
    },
    {
      "drug_id": "DrugBank::DB09053",
      "drug_name": "DB09053",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB09053 and MONDO:0004670 involves the inhibition of AKT1 (3702) by DB09053, which subsequently reduces the activation of TGFBR2 (7040), leading to decreased expression of PRLR (5617) and ultimately contributing to MONDO:0004670. An alternative pathway also originates with DB09053's inhibition of AKT1 (3702), but instead modulates TP53 (7157), which similarly downregulates PRLR (5617) and influences MONDO:0004670. Both pathways converge on PRLR as a key intermediate, highlighting its central role in connecting AKT1 inhibition to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 6
    },
    {
      "drug_id": "DrugBank::DB06292",
      "drug_name": "DB06292",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB06292 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB06292, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRLR (5617), ultimately influencing MONDO:0004670. Alternatively, DB06292 may also modulate MONDO:0004670 through NFKB1 (4790) by downregulating TP53 (7157), another upstream regulator of PRLR (5617). Both pathways converge on PRLR, highlighting its central role in connecting DB06292's effects to MONDO:0004670 through NFKB1-mediated regulation of TGFB1 or TP53.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 7
    },
    {
      "drug_id": "DrugBank::DB00331",
      "drug_name": "DB00331",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00331 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a sequential pathway mediated by key genes. DB00331 targets the gene FOXO3 (2309), which regulates the TP53 gene (7157). TP53, in turn, influences the expression of PRKCA (5617), a gene implicated in the pathogenesis of MONDO:0004670. This pathway suggests that DB00331 may modulate disease-related processes through FOXO3-mediated regulation of TP53 and subsequent effects on PRKCA activity. No alternative pathways were provided to integrate into this narrative.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 8
    },
    {
      "drug_id": "DrugBank::DB01232",
      "drug_name": "DB01232",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01232 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a sequential pathway mediated by key intermediate genes. DB01232 targets the gene *TP53* (Entrez ID: 7157), a central tumor suppressor that regulates cell cycle arrest and apoptosis. Activation or modulation of *TP53* subsequently influences *PRKAA1* (Entrez ID: 5562), a gene encoding a subunit of AMP-activated protein kinase (AMPK), which plays a critical role in cellular energy homeostasis. Dysregulation of *PRKAA1* has been implicated in the pathogenesis of MONDO:0004670, suggesting that DB01232 may indirectly affect disease progression through this *TP53*-*PRKAA1* axis. No alternative pathways were provided in the connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 9
    },
    {
      "drug_id": "DrugBank::DB06343",
      "drug_name": "DB06343",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB06343 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB06343 targets the *IGF1R* gene (3480), which encodes the insulin-like growth factor 1 receptor. Activation or modulation of *IGF1R* influences the *TP53* gene (7157), a critical tumor suppressor involved in cell cycle regulation and apoptosis. *TP53* subsequently regulates the expression of *PRLR* (5617), the prolactin receptor gene, which plays a role in hormonal signaling pathways. Dysregulation of *PRLR* has been implicated in the pathogenesis of MONDO:0004670, suggesting that DB06343 may indirectly affect the disease through this IGF1R-TP53-PRLR axis. No alternative pathways were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 10
    },
    {
      "drug_id": "DrugBank::DB08912",
      "drug_name": "DB08912",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08912 and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB08912 targets the BRAF gene (673), which activates the TP53 gene (7157). TP53 then regulates the expression of PRKCA (5617), a kinase implicated in the pathogenesis of MONDO:0004670. This pathway suggests that DB08912 may influence the disease through BRAF-mediated TP53 activation and subsequent PRKCA modulation. No alternative paths were provided, so this represents the sole known connection.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 11
    },
    {
      "drug_id": "DrugBank::DB11638",
      "drug_name": "DB11638",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11638 and MONDO:0004670 involves the inhibition of FOS (2353), which subsequently downregulates TGFB1 (7040), leading to reduced expression of PRL (5617) and ultimately contributing to MONDO:0004670. An alternative pathway also begins with DB11638 inhibiting FOS (2353), but instead modulates IL2 (3558), which then affects FOXP3 (51311) to influence MONDO:0004670. Both pathways converge on FOS as the key intermediate, highlighting its central role in mediating the effects of DB11638 through distinct downstream targets (TGFB1-PRL or IL2-FOXP3) to impact MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 12
    },
    {
      "drug_id": "DrugBank::DB08881",
      "drug_name": "DB08881",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08881 (a chemical entity) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB08881 targets the BRAF gene (673), which activates the TP53 gene (7157). TP53 then regulates the expression of PRKCA (5617), a kinase implicated in cellular signaling pathways. Dysregulation of PRKCA is directly associated with MONDO:0004670, suggesting that DB08881's modulation of BRAF and subsequent effects on TP53 and PRKCA may influence disease mechanisms. This pathway highlights the central roles of BRAF, TP53, and PRKCA in connecting the chemical to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 13
    },
    {
      "drug_id": "DrugBank::DB00437",
      "drug_name": "DB00437",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00437 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene NFE2L2 (4780), which subsequently activates either TGFB1 (7040) or TP53 (7157), both of which converge on PRKCA (5617) to influence the disease. In the first path, NFE2L2 upregulates TGFB1, a cytokine involved in signaling pathways, which then modulates PRKCA, a kinase implicated in disease processes. Alternatively, NFE2L2 may also regulate TP53, a tumor suppressor gene, which similarly interacts with PRKCA to mediate the disease outcome. Both pathways highlight the central roles of NFE2L2 as the initial drug target and PRKCA as the final effector linking these molecular interactions to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 14
    },
    {
      "drug_id": "DrugBank::DB10551",
      "drug_name": "DB10551",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB10551 and MONDO:0004670 involves the gene PPARA (5465), which is directly targeted by DB10551. PPARA then regulates TGFB1 (7040), a key cytokine that influences PRKAA1 (5617), a central player in energy homeostasis and cellular stress responses, ultimately contributing to MONDO:0004670. An alternative pathway also originates with PPARA activation by DB10551 but instead modulates TP53 (7157), a tumor suppressor gene that further interacts with PRKAA1 to influence the same disease outcome. Both pathways converge on PRKAA1, highlighting its pivotal role in connecting DB10551's effects to MONDO:0004670 through PPARA-mediated regulation of either TGFB1 or TP53.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 15
    },
    {
      "drug_id": "DrugBank::DB00762",
      "drug_name": "DB00762",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00762 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene *TP53* (7157), which subsequently regulates *PRLR* (5617), a gene directly associated with the disease. An alternative pathway also originates with DB00762 acting on *TP53*, but instead of targeting *PRLR*, it influences *IL2* (3558), which then modulates *FOXP3* (51311), another gene linked to MONDO:0004670. Both pathways converge on the disease through distinct but interconnected gene regulatory mechanisms, with *TP53* serving as the central intermediate connecting the drug's action to downstream disease-related genes.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 16
    },
    {
      "drug_id": "DrugBank::DB00412",
      "drug_name": "DB00412",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00412 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade through key intermediate genes. DB00412 targets **5045 (F2)**, a gene encoding coagulation factor II (thrombin), which subsequently interacts with **7040 (TGFB1)**, a cytokine involved in transforming growth factor-beta signaling. TGFB1 then regulates **5617 (PRL)**, the gene for prolactin, which has been implicated in MONDO:0004670. This pathway suggests that DB00412 may influence the disease through a thrombin-mediated modulation of TGFB1 signaling, ultimately affecting prolactin-related mechanisms. No alternative paths were provided to integrate.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 17
    },
    {
      "drug_id": "DrugBank::DB01234",
      "drug_name": "DB01234",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01234 and MONDO:0004670 involves a cascade of molecular interactions mediated by key intermediate genes. DB01234 targets the TP53 gene (11200), which regulates the TP53 signaling pathway. This pathway subsequently influences the expression of PRKAR1A (7157), a regulatory subunit of protein kinase A. PRKAR1A then modulates the activity of PRKACA (5617), the catalytic subunit of protein kinase A, which is critically involved in the pathogenesis of MONDO:0004670. This sequential pathway highlights the central roles of TP53, PRKAR1A, and PRKACA in connecting DB01234 to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 18
    },
    {
      "drug_id": "DrugBank::DB11842",
      "drug_name": "DB11842",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11842 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB11842 targets the gene TP53 (Entrez ID: 7157), a critical tumor suppressor, which directly regulates PRKAA1 (Entrez ID: 55617), a key component of the AMP-activated protein kinase (AMPK) pathway. Dysregulation of PRKAA1 is associated with MONDO:0004670, suggesting that DB11842 may influence the disease through TP53-mediated modulation of AMPK signaling. This pathway highlights TP53 and PRKAA1 as central intermediates connecting the drug's action to the disease phenotype. No alternative paths were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 19
    },
    {
      "drug_id": "DrugBank::DB00460",
      "drug_name": "DB00460",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00460 and MONDO:0004670 involves the activation of YWHAZ (10413), which subsequently inhibits TGFB1 (7040), leading to reduced PRKCA (5617) activity and ultimately contributing to MONDO:0004670. An alternative pathway also initiates with DB00460 activating YWHAZ (10413), which then upregulates TP53 (7157), further suppressing PRKCA (5617) and influencing MONDO:0004670. Both pathways converge on PRKCA (5617) as a key intermediate, highlighting its central role in connecting DB00460 to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 20
    },
    {
      "drug_id": "DrugBank::DB00514",
      "drug_name": "DB00514",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00514 and MONDO:0004670 involves IL3 (3605) as the initial target, which subsequently activates IL3RA (3558), leading to the modulation of PRLR (51311) and ultimately contributing to MONDO:0004670. Alternatively, DB00514 may also act through IL3 (3605) to influence TGFB1 (7040), which then regulates PRKCA (5617), providing a secondary pathway to MONDO:0004670. Both pathways converge on key intermediates—IL3, IL3RA, and PRLR in the primary path, and TGFB1 and PRKCA in the secondary path—highlighting their central roles in connecting DB00514 to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 21
    },
    {
      "drug_id": "DrugBank::DB12480",
      "drug_name": "DB12480",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB12480 and MONDO:0004670 involves EGFR (1956) as the initial target, which activates TGFB1 (7040), leading to PRLR (5617) signaling and ultimately contributing to MONDO:0004670. An alternative pathway also begins with EGFR (1956) but diverges through IL2 (3558) and FOXP3 (51311), suggesting a potential immune-regulatory route to the same outcome. Both pathways highlight EGFR as a central intermediary, with TGFB1 and IL2 serving as key downstream mediators influencing distinct molecular cascades linked to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 22
    },
    {
      "drug_id": "DrugBank::DB00746",
      "drug_name": "DB00746",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00746 (hypothetical drug) and MONDO:0004670 (hypothetical disease) involves the inhibition of HIF1A (3091) by DB00746, which subsequently downregulates TGFB1 (7040), a key regulator of PRL (5617), ultimately reducing PRL-associated pathways implicated in MONDO:0004670. An alternative pathway also originates with HIF1A inhibition but instead modulates TP53 (7157), which further suppresses PRL (5617), reinforcing the downstream effect on the disease. Both pathways converge on PRL as a central intermediate, highlighting its critical role in connecting DB00746's action to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 23
    },
    {
      "drug_id": "DrugBank::DB00641",
      "drug_name": "DB00641",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00641 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB00641 targets the gene PKM (5315), which encodes pyruvate kinase, a key enzyme in glycolysis. PKM regulates the activity of TP53 (7157), a critical tumor suppressor gene involved in cell cycle control and apoptosis. TP53, in turn, modulates the expression of PRKAA1 (5617), a subunit of AMP-activated protein kinase (AMPK), which plays a central role in cellular energy homeostasis. Dysregulation of PRKAA1 is associated with MONDO:0004670, suggesting that DB00641 may influence the disease through this PKM-TP53-PRKAA1 pathway. No alternative connections were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 24
    },
    {
      "drug_id": "DrugBank::DB01259",
      "drug_name": "DB01259",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01259 and MONDO:0004670 involves EGFR (1956) as the initial target, which subsequently activates TGFB1 (7040), leading to PRL (5617) modulation and ultimately contributing to MONDO:0004670. An alternative pathway also begins with EGFR (1956) but instead influences IL2 (3558), which then interacts with TNFRSF11A (51311) to reach the same outcome. Both pathways converge on MONDO:0004670, with EGFR serving as the common upstream regulator, while TGFB1/PRL and IL2/TNFRSF11A represent distinct intermediate cascades.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 25
    },
    {
      "drug_id": "DrugBank::DB08815",
      "drug_name": "DB08815",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08815 and MONDO:0004670 (a disease entity) involves a cascade through intermediate genes and pathways. DB08815 interacts with the gene **10105 (PRKAR2A)**, which encodes a regulatory subunit of protein kinase A (PKA). This interaction may modulate PKA activity, subsequently affecting **7157 (TP53)**, a critical tumor suppressor gene involved in cell cycle regulation and apoptosis. Altered TP53 function can then influence **5617 (PRL)**, a prolactin gene implicated in hormonal signaling pathways, ultimately contributing to the pathological processes associated with MONDO:0004670. This pathway highlights the potential role of PKA-mediated TP53 regulation and prolactin signaling in the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 26
    },
    {
      "drug_id": "DrugBank::DB00661",
      "drug_name": "DB00661",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00661 and MONDO:0004670 involves the upregulation of **IGF1R (3479)**, which activates **TGFBR2 (7040)**, leading to increased expression of **PRLR (5617)** and ultimately contributing to MONDO:0004670. An alternative pathway involves DB00661 upregulating **APOE (3486)**, which then enhances **TP53 (7157)** activity, further promoting **PRLR (5617)** expression and linking to MONDO:0004670. Both pathways converge on **PRLR (5617)** as a central intermediate, suggesting its pivotal role in connecting DB00661 to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 27
    },
    {
      "drug_id": "DrugBank::DB13923",
      "drug_name": "DB13923",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB13923 (a chemical entity) and MONDO:0004670 (a disease) involves a sequential pathway mediated by key intermediate genes. DB13923 targets F7 (coagulation factor VII, encoded by gene 2157), which activates the TGFB1 pathway (via gene 7040). TGFB1 then regulates PRLR (prolactin receptor, encoded by gene 5617), ultimately contributing to the disease phenotype (MONDO:0004670). This pathway suggests that DB13923 may influence disease mechanisms through a cascade involving coagulation factors, TGF-β signaling, and prolactin receptor modulation.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 28
    },
    {
      "drug_id": "DrugBank::DB09274",
      "drug_name": "DB09274",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB09274 and MONDO:0004670 involves the suppression of NFKBIA (4780), a key inhibitor of NF-κB signaling, leading to downstream activation of TGFB1 (7040), which promotes PRL (5617) expression, ultimately contributing to MONDO:0004670. Alternatively, DB09274 may also modulate IL2 (4772), which influences IL2RA (3558) signaling, subsequently altering FOXP3 (51311) activity, another pathway implicated in MONDO:0004670. Both pathways converge on immune and inflammatory regulatory mechanisms, with NFKBIA/TGFB1/PRL and IL2/IL2RA/FOXP3 serving as central intermediates.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 29
    },
    {
      "drug_id": "DrugBank::DB00571",
      "drug_name": "DB00571",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00571 and MONDO:0004670 involves the inhibition of **NFKBIA (9021)** by DB00571, leading to reduced suppression of **NFKB1 (3558)**, which subsequently activates **IL6 (3569)**, ultimately contributing to MONDO:0004670. An alternative pathway involves DB00571's interaction with **NFKB1 (4780)**, which directly modulates **TGFB1 (7040)**, followed by the regulation of **PRKCA (5617)**, further influencing MONDO:0004670. Both pathways converge on key inflammatory and signaling intermediates (NFKB1, IL6, TGFB1, PRKCA), highlighting their central roles in connecting DB00571 to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 30
    },
    {
      "drug_id": "DrugBank::DB04115",
      "drug_name": "DB04115",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB04115 and MONDO:0004670 involves the gene *TP53* (7157), which connects directly to *PRKAA1* (5617), a key regulator of energy metabolism, ultimately leading to MONDO:0004670. An alternative pathway involves DB04115 influencing *IL1B* (3558) through *ACHE* (196), with *IL1B* then interacting with *FASLG* (51311) to reach MONDO:0004670. Additionally, DB04115 may act via *YAP1* (10413), which modulates *TGFB1* (7040), subsequently converging on *PRKAA1* (5617) to link to the same outcome. These pathways highlight the central roles of *TP53*, *PRKAA1*, *IL1B*, and *YAP1* in mediating the connection between DB04115 and MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 31
    },
    {
      "drug_id": "DrugBank::DB11672",
      "drug_name": "DB11672",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11672 and MONDO:0004670 involves the inhibition of PIK3CA (5290), which subsequently reduces IL6 (3558) activity, leading to decreased expression of FOSL1 (51311) and ultimately contributing to MONDO:0004670. An alternative pathway involves DB11672 targeting NFKB1 (4790), which modulates TGFB1 (7040) signaling, thereby influencing PRKCA (5617) activity and its association with MONDO:0004670. Both pathways converge on key intermediate genes—PIK3CA, IL6, and FOSL1 in the primary path, and NFKB1, TGFB1, and PRKCA in the secondary path—highlighting their roles in connecting DB11672 to the condition.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 32
    },
    {
      "drug_id": "DrugBank::DB01132",
      "drug_name": "DB01132",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01132 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB01132 targets the gene *F7* (coagulation factor VII), which influences *TGFB1* (transforming growth factor beta 1). *TGFB1* then modulates *PRL* (prolactin), a hormone that plays a role in cellular proliferation and differentiation. Finally, *PRL* is associated with MONDO:0004670, suggesting a potential pathway through coagulation and growth factor signaling leading to disease involvement. This connection highlights the central roles of *F7*, *TGFB1*, and *PRL* in bridging the pharmacological action of DB01132 to the disease state.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 33
    },
    {
      "drug_id": "DrugBank::DB08895",
      "drug_name": "DB08895",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08895 and MONDO:0004670 involves the inhibition of **IL1R1 (IL-1 receptor type 1, Gene ID: 3558)** via **EGF (Gene ID: 1950)**, leading to downstream effects on **FZD4 (Gene ID: 8322)** and ultimately contributing to MONDO:0004670. Alternatively, DB08895 may also act through EGF to modulate **TGFB1 (Gene ID: 7040)**, which influences **PRL (Gene ID: 5617)** as a secondary pathway linked to the same condition. Both pathways converge on MONDO:0004670, with EGF serving as a central intermediate connecting DB08895 to these distinct but related mechanisms.  \n\n*(Note: The summary assumes FZD4 (Gene ID: 8322) is implied in the first path based on the provided MONDO:0004670 connection, though it was not explicitly listed in the given paths. If this assumption is incorrect, the summary should be adjusted to exclude FZD4.)*",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 34
    },
    {
      "drug_id": "DrugBank::DB00608",
      "drug_name": "DB00608",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00608 (a drug) and MONDO:0004670 (a disease) involves a cascade through specific genes. DB00608 targets the gene *TP53* (7157), which plays a central role in regulating cell cycle arrest and apoptosis. *TP53* activation influences the expression of *PRKCA* (5617), a protein kinase involved in signal transduction pathways. Dysregulation of *PRKCA* is associated with the pathological processes underlying MONDO:0004670. This pathway (DB00608 → *TP53* → *PRKCA* → MONDO:0004670) highlights the critical intermediary roles of *TP53* and *PRKCA* in connecting the drug's action to the disease. No alternative paths were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 35
    },
    {
      "drug_id": "DrugBank::DB02513",
      "drug_name": "DB02513",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB02513 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB02513, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRKCA (5617), ultimately influencing the development of MONDO:0004670. Alternatively, DB02513 may also act through NFKB1 (4790) to modulate TP53 (7157), which further regulates PRKCA (5617), contributing to the same phenotypic outcome. Both pathways converge on PRKCA (5617), highlighting its central role in mediating the effects of DB02513 on MONDO:0004670 through either TGFB1- or TP53-dependent mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 36
    },
    {
      "drug_id": "DrugBank::DB06603",
      "drug_name": "DB06603",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB06603 and MONDO:0004670 (a disease entity) involves a sequential pathway mediated by specific genes. DB06603 targets the gene **HDAC4**, which regulates **TP53**, a key tumor suppressor gene. TP53, in turn, influences **PRKCA**, a protein kinase involved in signal transduction. Finally, PRKCA modulates **MAPK1**, a central component of the MAP kinase pathway, which is directly associated with MONDO:0004670. This pathway highlights the critical roles of HDAC4, TP53, PRKCA, and MAPK1 in connecting DB06603 to the disease through a cascade of gene regulatory and signaling events.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 37
    },
    {
      "drug_id": "DrugBank::DB00184",
      "drug_name": "DB00184",
      "score": 1.0,
      "mechanism_story": "The primary mechanism linking DB00184 to MONDO:0004670 involves the activation of the TP53 gene (7157), which subsequently upregulates PRLR (5617), a key intermediate directly associated with MONDO:0004670. Alternatively, DB00184 may also influence MONDO:0004670 through two secondary pathways: (1) by modulating IL1B (3553), which activates IL1RN (3558) and then targets CASP1 (51311), or (2) via IL1B (3553) inducing TGFB1 (7040), which further upregulates PRLR (5617). These pathways converge on PRLR or CASP1, highlighting their central roles in connecting DB00184 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 38
    },
    {
      "drug_id": "DrugBank::DB09086",
      "drug_name": "DB09086",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB09086 (Nitrofurantoin) and MONDO:0004670 (Fanconi syndrome) involves the inhibition of NFKB1 (4790), which subsequently downregulates TGFB1 (7040), leading to reduced expression of PRKDC (5617), a key DNA repair gene implicated in Fanconi syndrome. Alternatively, DB09086 may also inhibit NFKB1 (4790), which then suppresses TP53 (7157), further contributing to the downregulation of PRKDC (5617) and the development of Fanconi syndrome. Both pathways converge on PRKDC dysfunction, highlighting its central role in connecting NFKB1-mediated signaling to the pathological features of Fanconi syndrome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 39
    },
    {
      "drug_id": "DrugBank::DB13751",
      "drug_name": "DB13751",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB13751 and MONDO:0004670 involves the inhibition of TLR4 (7099) by DB13751, which subsequently reduces the activation of TGFB1 (7040). This downregulation of TGFB1 leads to decreased expression of PRL (5617), a key intermediate implicated in MONDO:0004670. Alternatively, DB13751's inhibition of TLR4 (7099) may also suppress IL1R1 (3558), thereby reducing the activity of FKBP5 (51311), another gene associated with MONDO:0004670. Both pathways converge through TLR4 inhibition but diverge in their downstream effects, involving either the TGFB1-PRL or IL1R1-FKBP5 axes to influence MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 40
    },
    {
      "drug_id": "DrugBank::DB11817",
      "drug_name": "DB11817",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11817 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions mediated by key genes. DB11817 targets JAK1 (gene ID 3716), a tyrosine kinase that regulates the IL2RA (gene ID 3558) signaling pathway. IL2RA activation subsequently influences FOXP3 (gene ID 51311), a critical transcription factor for regulatory T-cell function. Dysregulation of FOXP3 is directly associated with MONDO:0004670, suggesting that DB11817 may modulate disease-relevant pathways through this JAK1-IL2RA-FOXP3 axis. No alternative pathways were identified in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 41
    },
    {
      "drug_id": "DrugBank::DB00169",
      "drug_name": "DB00169",
      "score": 1.0,
      "mechanism_story": "The primary mechanism linking DB00169 (TP53) to MONDO:0004670 (Fanconi anemia) involves TP53's regulation of PRKRA (7157), which subsequently modulates PRKDC (5617), a key DNA repair protein implicated in Fanconi anemia. Alternatively, TP53 may influence Fanconi anemia through PRKRA's interaction with IL2RG (3558), which activates AKT1S1 (51311), another component linked to the disease. A secondary pathway involves TP53's upregulation of ESR1 (2099), leading to TGFB1 (7040) activation, which also converges on PRKDC (5617). These pathways highlight PRKRA, PRKDC, IL2RG, AKT1S1, ESR1, and TGFB1 as central intermediates connecting TP53 to Fanconi anemia through DNA repair and signaling mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 42
    },
    {
      "drug_id": "DrugBank::DB12371",
      "drug_name": "DB12371",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB12371 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB12371, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRKCA (5617), ultimately influencing the development of MONDO:0004670. Alternatively, DB12371 may also modulate MONDO:0004670 through NFKB1 (4790) by downregulating TP53 (7157), another upstream regulator of PRKCA (5617). Both pathways converge on PRKCA, highlighting its central role in mediating the connection between DB12371 and MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 43
    },
    {
      "drug_id": "DrugBank::DB14845",
      "drug_name": "DB14845",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB14845 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB14845 targets JAK2 (gene ID 3716), a key kinase in the JAK-STAT signaling pathway. Activation of JAK2 leads to phosphorylation and activation of IL2RA (gene ID 3558), a subunit of the interleukin-2 receptor. This, in turn, modulates the activity of FOXP3 (gene ID 50943), a critical transcription factor for regulatory T-cell (Treg) function. Dysregulation of FOXP3 is directly associated with MONDO:0004670, highlighting the central role of the JAK2-IL2RA-FOXP3 axis in connecting the drug's action to the disease phenotype. No alternative pathways were identified in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 44
    },
    {
      "drug_id": "DrugBank::DB11588",
      "drug_name": "DB11588",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11588 (Pralatrexate) and MONDO:0004670 (Peripheral T-cell lymphoma) involves the inhibition of DHFR (3162) by DB11588, which disrupts folate metabolism and reduces thymidylate synthesis. This leads to impaired DNA replication and cell proliferation in rapidly dividing cells. The downstream effects involve TP53 (7157), a tumor suppressor gene that responds to DNA damage by regulating cell cycle arrest or apoptosis. The disruption of these processes ultimately contributes to the therapeutic targeting of PRKCQ (5617), a kinase implicated in T-cell activation and survival, thereby affecting the progression of peripheral T-cell lymphoma.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 45
    },
    {
      "drug_id": "DrugBank::DB15091",
      "drug_name": "DB15091",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB15091 (a drug) and MONDO:0004670 (a disease) involves a sequential pathway mediated by key genes. DB15091 targets JAK1 (gene 3716), which regulates IL2RA (gene 3558) through its role in cytokine signaling. IL2RA, in turn, modulates FOXP3 (gene 51311), a critical transcription factor for regulatory T-cell function. Dysregulation of FOXP3 is directly associated with MONDO:0004670, suggesting that DB15091 may influence the disease through this JAK1-IL2RA-FOXP3 axis. No alternative pathways were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 46
    },
    {
      "drug_id": "DrugBank::DB01109",
      "drug_name": "DB01109",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01109 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene *PDPK1* (5196), which activates *TGFBR1* (7040), leading to downstream regulation of *PRKCA* (5617) and ultimately influencing the disease. An alternative pathway also originates with *PDPK1* (5196) but instead activates *TP53* (7157), which subsequently modulates *PRKCA* (5617) to affect the disease. Both pathways converge on *PRKCA* as a key intermediate, highlighting its central role in connecting DB01109's action to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 47
    },
    {
      "drug_id": "DrugBank::DB06448",
      "drug_name": "DB06448",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB06448 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of gene interactions. DB06448 targets the MAP2K1 gene (5609), which encodes a kinase that activates MAPK1 (7157), a key regulator of the MAPK signaling pathway. MAPK1 then modulates PRKCA (5617), a protein kinase implicated in cellular proliferation and survival. Dysregulation of PRKCA is directly associated with MONDO:0004670, suggesting that DB06448 may influence the disease through this MAP2K1-MAPK1-PRKCA axis. No alternative pathways are indicated in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 48
    },
    {
      "drug_id": "DrugBank::DB00995",
      "drug_name": "DB00995",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00995 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with NFE2L2 (4780), a key regulator of oxidative stress responses. NFE2L2 activation leads to downstream modulation of TGFB1 (7040), a cytokine involved in fibrotic pathways, which subsequently influences PRKCA (5617), a protein kinase implicated in disease pathogenesis. Alternatively, NFE2L2 may also regulate TP53 (7157), a tumor suppressor gene that further interacts with PRKCA, converging on the same disease endpoint. Both pathways highlight the central roles of NFE2L2 and PRKCA in connecting the drug's effects to the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 49
    },
    {
      "drug_id": "DrugBank::DB04951",
      "drug_name": "DB04951",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB04951 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB04951, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRKCA (5617), ultimately influencing the development of MONDO:0004670. Alternatively, DB04951 may also act through NFKB1 (4790) to modulate TP53 (7157), which further regulates PRKCA (5617), converging on the same downstream pathway. Both pathways highlight NFKB1 and PRKCA as central intermediates, with TGFB1 and TP53 serving as alternative mediators linking DB04951 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 50
    },
    {
      "drug_id": "DrugBank::DB01050",
      "drug_name": "DB01050",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01050 and MONDO:0004670 involves the gene **NFKB1 (4790)**, which is directly targeted by DB01050. NFKB1 then activates **TGFB1 (7040)**, a key regulator of the **PRL (5617)** gene, ultimately influencing the development of MONDO:0004670. Alternatively, NFKB1 may also act through **TP53 (7157)**, which similarly regulates PRL, providing a secondary pathway connecting DB01050 to MONDO:0004670. Both pathways converge on PRL, highlighting its central role in mediating the relationship between DB01050 and the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 51
    },
    {
      "drug_id": "DrugBank::DB11693",
      "drug_name": "DB11693",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB11693 (a drug) and MONDO:0004670 (a disease) involves DB08879 as a key intermediate. DB11693 interacts with DB08879, which subsequently associates with MONDO:0004670, suggesting that DB08879 may mediate the drug's influence on the disease. No additional pathways or intermediates are implicated in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 52
    },
    {
      "drug_id": "DrugBank::DB00877",
      "drug_name": "DB00877",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00877 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene *TP53* (7157), which subsequently modulates *PRLR* (5617), a gene directly associated with the disease. This pathway suggests that DB00877 may influence disease progression through *TP53*-mediated regulation of *PRLR*. An alternative connection involves *TP53* activating *IL2RA* (3558), which then interacts with *FOXP3* (51311), another gene linked to the disease. This secondary pathway implies an additional mechanism where DB00877 could affect the disease via *TP53*-driven immune regulation through *IL2RA* and *FOXP3*. Both pathways highlight *TP53* as a central intermediary connecting the drug to the disease through distinct downstream targets.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 53
    },
    {
      "drug_id": "DrugBank::DB08882",
      "drug_name": "DB08882",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08882 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with HSPA5 (3309), a key gene encoding a heat shock protein. This interaction leads to downstream effects on TGFB1 (7040), a cytokine involved in fibrotic pathways, which subsequently modulates PRKCA (5617), a protein kinase implicated in disease pathogenesis. Alternatively, DB08882 may also influence MONDO:0004670 through HSPA5 by regulating TP53 (7157), a tumor suppressor gene, which similarly converges on PRKCA. Both pathways highlight PRKCA as a central intermediate connecting the drug's action to the disease, with HSPA5 serving as the initial molecular target.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 54
    },
    {
      "drug_id": "DrugBank::DB01261",
      "drug_name": "DB01261",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01261 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the NFKB1 gene (4790), which subsequently activates the TGFB1 gene (7040), leading to the modulation of PRL (5617) and ultimately contributing to the disease phenotype. An alternative pathway also begins with DB01261 acting on NFKB1 (4790), but instead of TGFB1, it influences TP53 (7157), which then regulates PRL (5617) to affect the disease. Both pathways converge on PRL as a key intermediate, highlighting its central role in connecting the drug's action to the disease outcome through distinct but related gene regulatory mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 55
    },
    {
      "drug_id": "DrugBank::DB01039",
      "drug_name": "DB01039",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01039 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the PPARA gene (5465), which subsequently activates TGFB1 (7040), leading to PRKCA (5617) modulation and ultimately influencing the disease. An alternative pathway also originates with PPARA (5465) but instead activates TP53 (7157), which then regulates PRKCA (5617) to contribute to the disease phenotype. Both pathways converge on PRKCA (5617) as a key intermediate, highlighting its central role in connecting drug-induced PPARA activation to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 56
    },
    {
      "drug_id": "DrugBank::DB08911",
      "drug_name": "DB08911",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08911 (a drug) and MONDO:0004670 (a disease) involves a cascade through key intermediate genes. DB08911 targets the MAP2K1 gene (MEK1), which activates the TP53 gene (p53), a critical tumor suppressor. TP53 then regulates the PRKCA gene (protein kinase C alpha), which subsequently influences disease pathways associated with MONDO:0004670. This sequential modulation of MAP2K1 → TP53 → PRKCA forms the core pathway connecting the drug to the disease. No alternative paths were provided, so this represents the sole known mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 57
    },
    {
      "drug_id": "DrugBank::DB00783",
      "drug_name": "DB00783",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00783 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the IL8 gene (3576), which subsequently activates the TGFB1 gene (7040). TGFB1 then modulates the PRL gene (5617), ultimately influencing the disease phenotype. Alternatively, DB00783 may also act through IL8 (3576) to regulate the IL1A gene (3558), which in turn interacts with the FOSL1 gene (51311) to contribute to the disease. Both pathways converge on IL8 as the central intermediate, highlighting its pivotal role in mediating the drug's potential effects on the disease through distinct downstream targets (TGFB1/PRL or IL1A/FOSL1).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 58
    },
    {
      "drug_id": "DrugBank::DB00467",
      "drug_name": "DB00467",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00467 and MONDO:0004670 involves the inhibition of TGFBR1 (864) by DB00467, which subsequently reduces signaling through TGF-β pathways. This leads to downregulation of TGFB1 (7040), a key cytokine in fibrotic processes, ultimately contributing to the modulation of PRKCA (5617) activity and affecting the pathology of MONDO:0004670. An alternative pathway also originates from TGFBR1 inhibition but instead impacts SMAD3 (7157), another central mediator of TGF-β signaling, which similarly converges on PRKCA to influence the disease outcome. Both pathways highlight the critical role of TGFBR1 as the initial target and PRKCA as the downstream effector linking DB00467 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 59
    },
    {
      "drug_id": "DrugBank::DB08908",
      "drug_name": "DB08908",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08908 and MONDO:0004670 involves the inhibition of **G6PD** (2597) by DB08908, leading to reduced activity of the **IL1R1** (3558) pathway, which subsequently affects **FASLG** (51311) signaling, ultimately contributing to MONDO:0004670. Alternatively, DB08908 may also influence **ELANE** (1994), which modulates **TGFB1** (7040) activity, further impacting **PRKCA** (5617) and its downstream effects on MONDO:0004670. Both pathways converge through key intermediates—**G6PD** and **IL1R1** in the primary path, and **ELANE** and **TGFB1** in the secondary path—highlighting their roles in the potential mechanisms linking DB08908 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 60
    },
    {
      "drug_id": "DrugBank::DB08916",
      "drug_name": "DB08916",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08916 and MONDO:0004670 involves EGFR (1956) as the initial target, which subsequently activates IL6 (3558), leading to PRLR (51311) signaling and ultimately contributing to MONDO:0004670. An alternative pathway also originates with EGFR (1956) but diverges through TGFB1 (7040), which then modulates PRL (5617) before reaching MONDO:0004670. Both pathways highlight EGFR as the central upstream regulator, with IL6 and TGFB1 serving as key intermediates that converge on prolactin-related signaling (via PRLR or PRL) to potentially influence the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 61
    },
    {
      "drug_id": "DrugBank::DB11132",
      "drug_name": "DB11132",
      "score": 1.0,
      "mechanism_story": "The provided connections indicate that DB11132 is directly linked to MONDO:0004670 through two distinct paths, both with equal weight (10.00). Since no intermediate entities (genes, pathways, or other biological components) are specified in either path, the summary is limited to the direct associations. Thus, DB11132 has a direct mechanistic relationship with MONDO:0004670, but the specific biological intermediaries or pathways involved cannot be inferred from the given data. Both connections suggest an equivalent likelihood of association, though the exact nature of these links remains unspecified.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 62
    },
    {
      "drug_id": "DrugBank::DB00481",
      "drug_name": "DB00481",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00481 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with ESR1 (2099), which subsequently modulates TGFB1 (7040), leading to PRLR (5617) activation and ultimately contributing to the disease phenotype. Alternatively, DB00481 may also influence MONDO:0004670 through ESR1-mediated regulation of TP53 (7157), which similarly converges on PRLR activation. Both pathways highlight ESR1 as the central upstream regulator, with PRLR serving as the key downstream effector connecting these molecular interactions to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 63
    },
    {
      "drug_id": "DrugBank::DB00398",
      "drug_name": "DB00398",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00398 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a sequential pathway mediated by key genes. DB00398 targets STAT3 (6775), which regulates IL2RA (3558), a gene encoding the alpha subunit of the interleukin-2 receptor. IL2RA activation subsequently influences FOXP3 (51311), a critical transcription factor for regulatory T-cell function. Dysregulation of FOXP3 is directly associated with MONDO:0004670, suggesting that DB00398 may modulate disease-relevant immune responses through this STAT3-IL2RA-FOXP3 axis. No alternative pathways were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 64
    },
    {
      "drug_id": "DrugBank::DB01698",
      "drug_name": "DB01698",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB01698 and MONDO:0004670 involves the inhibition of NFKB1 (4790) by DB01698, which subsequently reduces the expression of TGFB1 (7040), a key regulator of PRL (5617), ultimately influencing the development of MONDO:0004670. Alternatively, DB01698 may also act through NFKB1 (4790) to modulate TP53 (7157), which further regulates PRL (5617), contributing to the same phenotypic outcome. Both pathways converge on PRL (5617) as a central intermediate, highlighting its critical role in connecting the initial pharmacological action to the disease state.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 65
    },
    {
      "drug_id": "DrugBank::DB00091",
      "drug_name": "DB00091",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00091 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB00091 targets the gene *10105* (a specific gene identifier), which subsequently influences the activity of *7157* (TP53, a tumor suppressor gene). TP53 then regulates the expression of *5617* (PRLR, the prolactin receptor gene), which is directly associated with MONDO:0004670. This pathway suggests that DB00091 may modulate disease-related processes through TP53-mediated regulation of PRLR, highlighting the central roles of these genes in connecting the drug to the disease. No alternative pathways were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 66
    },
    {
      "drug_id": "DrugBank::DB09037",
      "drug_name": "DB09037",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB09037 and MONDO:0004670 involves the inhibition of EGFR (1956) by DB09037, which subsequently reduces the activity of IL6 (3568), leading to downregulation of PRLR (51311) and ultimately contributing to the modulation of MONDO:0004670. An alternative pathway also begins with DB09037's inhibition of EGFR (1956), but instead affects TGFB1 (7040), which then influences PRL (5617) to further impact MONDO:0004670. Both pathways converge on EGFR as the initial target, with downstream effects mediated through IL6 or TGFB1, highlighting the central role of EGFR signaling in connecting DB09037 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 67
    },
    {
      "drug_id": "DrugBank::DB00530",
      "drug_name": "DB00530",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00530 and MONDO:0004670 involves EGFR (1956) as the initial target, which subsequently activates IL6 (3568), leading to PRLR (51311) signaling and ultimately contributing to MONDO:0004670. An alternative pathway also originates with EGFR (1956) but diverges to TGFB1 (7040), which then modulates PRL (5617) before reaching MONDO:0004670. Both pathways highlight EGFR as the central intermediate, with downstream effects mediated either through IL6-PRLR or TGFB1-PRL interactions, suggesting multiple routes by which DB00530 may influence MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 68
    },
    {
      "drug_id": "DrugBank::DB00396",
      "drug_name": "DB00396",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB00396 (a drug) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB00396 targets the gene *TP53* (5241), which regulates the expression of *TP73* (7157). *TP73* subsequently modulates the activity of *PRKCA* (5617), a kinase implicated in cellular signaling pathways. Dysregulation of *PRKCA* is directly associated with the development of MONDO:0004670, suggesting that DB00396 may influence the disease through this TP53-TP73-PRKCA axis. No alternative pathways were identified in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 69
    },
    {
      "drug_id": "DrugBank::DB00871",
      "drug_name": "DB00871",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB00871 and MONDO:0004670 involves the inhibition of **IL2RA (interleukin 2 receptor subunit alpha, gene ID: 3558)** via the intermediate **CREBBP (CREB-binding protein, gene ID: 1385)**, which modulates immune responses and may contribute to the disease phenotype. Alternatively, DB00871 may also influence **TGFB1 (transforming growth factor beta 1, gene ID: 7040)** through **IL7R (interleukin 7 receptor, gene ID: 3605)**, subsequently affecting **PRKCA (protein kinase C alpha, gene ID: 5617)**, another key regulator of cellular signaling pathways implicated in MONDO:0004670. Both pathways converge on immune and inflammatory processes, with **CREBBP** and **TGFB1** serving as central intermediates.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 70
    },
    {
      "drug_id": "DrugBank::DB04272",
      "drug_name": "DB04272",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB04272 and MONDO:0004670 involves EGFR (1956) as the initial target, which activates TGFB1 (7040), leading to PRLR (5617) signaling and ultimately contributing to MONDO:0004670. An alternative pathway also begins with EGFR (1956) but instead modulates IL2 (3558), which influences FOXP3 (51311) activity, thereby connecting to MONDO:0004670. Both pathways converge on EGFR as the central intermediate, highlighting its pivotal role in mediating the effects of DB04272 through TGFB1-PRLR or IL2-FOXP3 signaling cascades.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 71
    },
    {
      "drug_id": "DrugBank::DB08877",
      "drug_name": "DB08877",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB08877 and MONDO:0004670 involves the inhibition of **JAK2 (3716)** by DB08877, leading to downstream suppression of **IL2RA (3558)** and subsequent modulation of **FASLG (51311)**, which is implicated in MONDO:0004670. Alternatively, DB08877 may also act through **CCL2 (6347)**, reducing its activity and thereby influencing **TGFB1 (7040)**, which further regulates **PRL (5617)**—a gene associated with MONDO:0004670. Both pathways converge on key immune and inflammatory mediators (JAK2-IL2RA-FASLG and CCL2-TGFB1-PRL), highlighting their roles in connecting DB08877 to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 72
    },
    {
      "drug_id": "DrugBank::DB00137",
      "drug_name": "DB00137",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB00137 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene CXCL8 (IL8, 3576), which activates IL6 (3568), leading to the regulation of IL1RL1 (51311) and ultimately contributing to the disease. Alternatively, DB00137 may also influence the disease through its effect on COL1A1 (1277), which modulates TGFB1 (7040), subsequently impacting PRL (5617) as a key intermediate. Both pathways converge on MONDO:0004670, with CXCL8/IL6/IL1RL1 and COL1A1/TGFB1/PRL serving as central gene-level mediators in these distinct but parallel connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 73
    },
    {
      "drug_id": "DrugBank::DB00073",
      "drug_name": "DB00073",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB00073 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with IL3 (3605), which subsequently modulates IL3RA (3558), leading to activation of STAT5B (51311) and ultimately contributing to the disease phenotype. Alternatively, DB00073 may also influence the disease through IL3 (3605) by first interacting with TGFB1 (7040), which then regulates PRL (5617), providing a secondary pathway to the same disease outcome. Both pathways converge on IL3 as the central intermediary, highlighting its pivotal role in connecting the drug's action to the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 74
    },
    {
      "drug_id": "DrugBank::DB00242",
      "drug_name": "DB00242",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB00242 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB00242 targets IL10 (gene ID: 3586), which modulates the expression of TGFB1 (gene ID: 7040). TGFB1, in turn, regulates PRLR (gene ID: 5617), a key gene implicated in MONDO:0004670. This pathway suggests that DB00242 may influence the disease through IL10-mediated TGFB1 signaling, ultimately affecting PRLR activity. No alternative paths were provided, so this represents the sole known connection.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 75
    },
    {
      "drug_id": "DrugBank::DB01593",
      "drug_name": "DB01593",
      "score": 0.9999998807907104,
      "mechanism_story": "The primary mechanistic link between DB01593 (a drug) and MONDO:0004670 (a disease) involves ILK (50943) as a key intermediate, which connects to the disease via IL1R2 (3558) and FOXO3 (51311), suggesting a pathway where DB01593 modulates ILK activity, potentially influencing IL1R2-mediated signaling and FOXO3-regulated processes. An alternative connection also involves ILK (50943) but diverges through TGFB1 (7040) and PRKCA (5617), indicating that DB01593 may additionally affect TGFB1 signaling and PRKCA-dependent pathways to impact the disease. Both pathways converge on MONDO:0004670, highlighting ILK as a central node bridging drug action to disease mechanisms through distinct but interconnected routes.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 76
    },
    {
      "drug_id": "DrugBank::DB01048",
      "drug_name": "DB01048",
      "score": 0.9999997615814209,
      "mechanism_story": "The primary mechanistic link between DB01048 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB01048 targets the IL2RA gene (6962), which encodes a subunit of the interleukin-2 receptor. This receptor interacts with IL2 (3558), a cytokine critical for immune regulation. IL2 signaling subsequently modulates the activity of FOXP3 (51311), a transcription factor essential for regulatory T-cell function. Dysregulation of FOXP3 is directly associated with MONDO:0004670, suggesting that DB01048 may influence the disease through this IL2RA-IL2-FOXP3 pathway. No alternative connections were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 77
    },
    {
      "drug_id": "DrugBank::DB00674",
      "drug_name": "DB00674",
      "score": 0.9999997615814209,
      "mechanism_story": "The primary mechanistic link between DB00674 (a pharmaceutical compound) and MONDO:0004670 (a disease) involves a cascade of molecular interactions. DB00674 targets **IL1RAP (9021)**, which modulates the activity of **IL1R1 (3558)**, a key receptor in the interleukin-1 signaling pathway. This interaction influences **AKT3 (51311)**, a serine/threonine kinase involved in cell survival and proliferation, ultimately contributing to the pathological processes associated with MONDO:0004670. The connection highlights the central roles of IL1RAP, IL1R1, and AKT3 in bridging the pharmacological action of DB00674 to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 78
    },
    {
      "drug_id": "DrugBank::DB08834",
      "drug_name": "DB08834",
      "score": 0.9999997615814209,
      "mechanism_story": "The primary mechanistic link between DB08834 and MONDO:0004670 involves the inhibition of IL2 (interleukin-2, gene ID 3558) via DB08834's interaction with IL2RA (gene ID 3559), ultimately contributing to MONDO:0004670. This pathway suggests that DB08834 may modulate immune responses through IL2 signaling disruption. Alternatively, DB08834 may also influence MONDO:0004670 through a secondary pathway involving DLD (dihydrolipoamide dehydrogenase, gene ID 1738), which interacts with PRKAA1 (gene ID 5562) and subsequently affects cellular energy metabolism via PRKAA1's role in AMPK signaling. Both pathways converge on MONDO:0004670, highlighting IL2 and PRKAA1 as key intermediates in these potential mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 79
    },
    {
      "drug_id": "DrugBank::DB00470",
      "drug_name": "DB00470",
      "score": 0.9999996423721313,
      "mechanism_story": "The primary mechanistic link between DB00470 and MONDO:0004670 involves the inhibition of TLR4 (7098), which subsequently reduces IL1B (3558) activation, leading to downregulation of IRAK4 (51311) and ultimately modulating the inflammatory response in MONDO:0004670. Alternatively, DB00470 may also act through TLR2 (7099), which inhibits TGFB1 (7040) signaling, thereby decreasing PRKCA (5617) activity and contributing to the same disease phenotype. Both pathways converge on key inflammatory mediators (TLR4/IL1B/IRAK4 and TLR2/TGFB1/PRKCA), highlighting their central roles in connecting DB00470 to MONDO:0004670.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 80
    },
    {
      "drug_id": "DrugBank::DB04861",
      "drug_name": "DB04861",
      "score": 0.9999996423721313,
      "mechanism_story": "The primary mechanistic link between DB04861 and MONDO:0004670 involves the inhibition of IL2 (3606) by DB04861, which subsequently reduces IL2RA (3558) activity, leading to altered IL2RB (51311) signaling and ultimately contributing to MONDO:0004670. Alternatively, DB04861 may also interact with NOS2 (4843), modulating TP53 (7157) expression, which in turn affects PRKCA (5617) activity, providing a secondary pathway linking DB04861 to MONDO:0004670. Both pathways converge through key intermediates—IL2/IL2RA/IL2RB and NOS2/TP53/PRKCA—highlighting their roles in the potential mechanisms underlying this association.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 81
    },
    {
      "drug_id": "DrugBank::DB08880",
      "drug_name": "DB08880",
      "score": 0.9999996423721313,
      "mechanism_story": "The primary mechanistic link between DB08880 and MONDO:0004670 involves the inhibition of STAT1 (6772) by DB08880, which subsequently reduces the activity of IL2RA (3558), a key regulator of immune response. This downregulation of IL2RA ultimately contributes to the phenotypic manifestations of MONDO:0004670. Alternatively, DB08880 may also influence MONDO:0004670 through STAT1-mediated suppression of TP53 (7157), leading to altered expression of PRKCA (5617), a kinase involved in cellular signaling pathways. Both pathways converge on MONDO:0004670, highlighting the central role of STAT1 as the critical intermediate connecting DB08880 to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 82
    },
    {
      "drug_id": "DrugBank::DB00910",
      "drug_name": "DB00910",
      "score": 0.9999995231628418,
      "mechanism_story": "The primary mechanistic link between DB00910 and MONDO:0004670 involves the gene IL2 (3606), which is targeted by DB00910, leading to downstream modulation of IL2RA (3558). This subsequently affects IL7R (51311), a key receptor in immune signaling, ultimately contributing to the phenotype associated with MONDO:0004670. Alternatively, DB00910 may also influence TNF (4790), which activates TGFB1 (7040), a cytokine regulating PRL (5617), another critical player in immune and inflammatory pathways linked to MONDO:0004670. Both pathways converge on immune-related intermediates, with IL2 and TNF serving as central nodes connecting DB00910 to the disease outcome.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 83
    },
    {
      "drug_id": "DrugBank::DB12917",
      "drug_name": "DB12917",
      "score": 0.9999995231628418,
      "mechanism_story": "The primary mechanistic link between DB12917 and MONDO:0004670 involves IL7R (3605), which connects to IL2 (3558), leading to PRL (51311) and ultimately to the disease. IL7R activation may modulate IL2 signaling, which in turn influences PRL expression, potentially contributing to disease pathogenesis. Alternatively, IL7R also interacts with TGFB1 (7040), which regulates PRLR (5617), suggesting an additional pathway where TGFB1-mediated PRLR signaling could play a role in the disease. Both pathways converge on prolactin-related mechanisms, with IL7R serving as a central intermediate connecting DB12917 to MONDO:0004670 through distinct cytokine and receptor interactions.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 84
    },
    {
      "drug_id": "DrugBank::DB06655",
      "drug_name": "DB06655",
      "score": 0.9999990463256836,
      "mechanism_story": "The primary mechanistic link between DB06655 and MONDO:0004670 involves the inhibition of **TLR4 (7099)** by DB06655, which subsequently reduces the activation of **IL1R1 (3558)**, leading to decreased signaling through **FASLG (51311)** and ultimately modulating the disease phenotype (MONDO:0004670). Alternatively, DB06655 may also act through **NFKBIA (4790)**, suppressing its degradation and thereby inhibiting **TGFB1 (7040)** activity, which in turn downregulates **PRKCA (5617)** signaling to influence the same disease outcome. Both pathways converge on MONDO:0004670, with TLR4/IL1R1/FASLG and NFKBIA/TGFB1/PRKCA serving as key intermediate hubs in these connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 85
    },
    {
      "drug_id": "DrugBank::DB00159",
      "drug_name": "DB00159",
      "score": 0.999998927116394,
      "mechanism_story": "The primary mechanistic link between DB00159 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the IL1R1 gene (627), which activates the IL-1 signaling pathway. This leads to downstream activation of IL1RAP (3558), a coreceptor in the IL-1 pathway, ultimately contributing to the disease phenotype. An alternative pathway also originates with IL1R1 (627) but diverges through TGFB1 (7040), a cytokine that modulates PRL (5617), a hormone implicated in the disease. Both pathways converge on MONDO:0004670, with IL1R1 serving as the central intermediary connecting DB00159 to the disease via either IL1RAP or the TGFB1-PRL axis.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 86
    },
    {
      "drug_id": "DrugBank::DB16650",
      "drug_name": "DB16650",
      "score": 0.9999986886978149,
      "mechanism_story": "The primary mechanistic link between DB16650 and MONDO:0004670 involves a pathway mediated by the intermediate genes IFNA2 (3439), IRF7 (3558), and FOSL1 (51311). DB16650 may influence IFNA2, which subsequently activates IRF7, a key regulator of interferon signaling. IRF7 then modulates the expression of FOSL1, a transcription factor implicated in cellular proliferation and differentiation. The altered activity of FOSL1 ultimately contributes to the pathological processes associated with MONDO:0004670. This pathway highlights the central roles of interferon signaling (via IFNA2 and IRF7) and transcriptional regulation (via FOSL1) in connecting DB16650 to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 87
    },
    {
      "drug_id": "DrugBank::DB00624",
      "drug_name": "DB00624",
      "score": 0.9999982118606567,
      "mechanism_story": "The primary mechanistic link between DB00624 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with ILK (50943), which subsequently modulates AKT1 (3558). AKT1 then influences PRKAA2 (51311), a key regulator of cellular energy homeostasis, ultimately contributing to the disease phenotype. Alternatively, DB00624 may also act through ILK (50943) to affect TGFB1 (7040), which in turn regulates PRKAR1A (5617), a component of the cAMP-dependent protein kinase pathway, providing a secondary route to the disease. Both pathways converge on ILK as a central intermediary, highlighting its role in bridging the drug's effects to downstream disease-related mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 88
    },
    {
      "drug_id": "DrugBank::DB12159",
      "drug_name": "DB12159",
      "score": 0.9999980926513672,
      "mechanism_story": "The primary mechanistic link between DB12159 and MONDO:0004670 involves a sequential pathway mediated by IL13 (3596), which activates IL13RA1 (3558). This interaction subsequently engages FOSL1 (51311), a transcription factor implicated in cellular proliferation and differentiation, ultimately contributing to the phenotypic manifestations of MONDO:0004670. The pathway highlights the central roles of IL13 signaling through its receptor IL13RA1 and downstream FOSL1 activation in connecting DB12159 to the disease state. No alternative paths were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 89
    },
    {
      "drug_id": "DrugBank::DB00203",
      "drug_name": "DB00203",
      "score": 0.999997615814209,
      "mechanism_story": "The primary mechanistic link between DB00203 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the gene *CYP3A4 (3627)*, which then modulates *IL2 (3558)*, a cytokine critical for immune regulation. *IL2* further influences *FASLG (51311)*, a key apoptosis-related gene, ultimately contributing to the disease phenotype. Alternatively, DB00203 may also act through *CYP3A4 (3627)* to affect *TGFB1 (7040)*, a cytokine involved in cell growth and differentiation, which subsequently regulates *PRLR (5617)*, a prolactin receptor gene linked to immune and metabolic pathways, thereby connecting to the disease. Both pathways highlight the central role of *CYP3A4* as the initial mediator, with downstream effects converging on immune and apoptotic mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 90
    },
    {
      "drug_id": "DrugBank::DB00201",
      "drug_name": "DB00201",
      "score": 0.9999959468841553,
      "mechanism_story": "The primary mechanistic link between DB00201 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with TNF (Tumor Necrosis Factor, gene ID 7124), which subsequently modulates IL2 (Interleukin-2, gene ID 3558) and then PTGS2 (Prostaglandin-Endoperoxide Synthase 2, gene ID 51311), ultimately influencing the disease. Alternatively, DB00201 may also act through TNF (7124) to affect TGFB1 (Transforming Growth Factor Beta 1, gene ID 7040), which then regulates PRL (Prolactin, gene ID 5617) before impacting the disease. Both pathways converge on TNF as the key intermediary, highlighting its central role in connecting the drug's action to the disease outcome through inflammatory and immune-related signaling cascades.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 91
    },
    {
      "drug_id": "DrugBank::DB06168",
      "drug_name": "DB06168",
      "score": 0.9999946355819702,
      "mechanism_story": "The primary mechanistic link between DB06168 and MONDO:0004670 involves the inhibition of IL1B (3553) by DB06168, which subsequently reduces the activation of IL1R1 (3558), leading to downstream modulation of IRAK4 (51311) and ultimately influencing MONDO:0004670. An alternative pathway also originates with DB06168's inhibition of IL1B (3553), which then affects TGFB1 (7040), altering the expression of PRKCA (5617) and contributing to the same phenotypic outcome (MONDO:0004670). Both pathways converge on IL1B as the central intermediary, highlighting its pivotal role in connecting DB06168's action to the disease state.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 92
    },
    {
      "drug_id": "DrugBank::DB01281",
      "drug_name": "DB01281",
      "score": 0.9999934434890747,
      "mechanism_story": "The primary mechanistic link between DB01281 and MONDO:0004670 involves the IL6R gene (intermediate node 3558), which connects through a pathway initiated by DB01281's interaction with CXCL8 (4283), leading to IL6R activation and ultimately to MONDO:0004670. Alternatively, DB01281 may also influence MONDO:0004670 through a secondary pathway involving CTNNA1 (1493), which interacts with TGFB1 (7040) and PRKCA (5617). Both pathways converge on MONDO:0004670, with IL6R and TGFB1 serving as key intermediates in the inflammatory and signaling cascades, respectively.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 93
    },
    {
      "drug_id": "DrugBank::DB00822",
      "drug_name": "DB00822",
      "score": 0.9999899864196777,
      "mechanism_story": "The primary mechanistic link between DB00822 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with the IL1B gene (960), which subsequently activates the IL1R1 gene (3558). This leads to downstream signaling through IRAK4 (51311), ultimately contributing to the disease phenotype. An alternative pathway also originates with DB00822's interaction with IL1B (960), but instead triggers the TP53 gene (7157), which then modulates PRKCD (5617) to influence the disease outcome. Both pathways converge on IL1B as the central intermediate, highlighting its pivotal role in connecting the drug's action to the disease through distinct downstream effectors (IL1R1/IRAK4 or TP53/PRKCD).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 94
    },
    {
      "drug_id": "DrugBank::DB06612",
      "drug_name": "DB06612",
      "score": 0.9999880790710449,
      "mechanism_story": "The primary mechanistic link between DB06612 and MONDO:0004670 involves the inhibition of IL4R (3567) by DB06612, which subsequently reduces the activation of IL13 (3558), leading to decreased signaling through IL13RA1 (51311) and ultimately modulating the disease phenotype (MONDO:0004670). Alternatively, DB06612's inhibition of IL4R (3567) may also downregulate TGFB1 (7040), which in turn reduces the expression of PRL (5617), contributing to an alternative pathway influencing the same disease outcome (MONDO:0004670). Both pathways converge on MONDO:0004670 through distinct but interconnected cytokine signaling mechanisms centered on IL4R inhibition.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 95
    },
    {
      "drug_id": "DrugBank::DB00563",
      "drug_name": "DB00563",
      "score": 0.9999827146530151,
      "mechanism_story": "The primary mechanistic link between DB00563 and MONDO:0004670 involves the IL1R1 gene (3558), which is activated downstream of CSF1R (1437) signaling. DB00563 may influence CSF1R, leading to IL1R1 activation and subsequent progression to MONDO:0004670. Alternatively, DB00563 could act through IL1A (3552), which triggers PRKCA (7040) and MAPK3 (5617), another pathway converging on MONDO:0004670. Both pathways highlight the central roles of CSF1R and IL1R1 in the primary mechanism, and IL1A and PRKCA in the secondary route, suggesting multiple inflammatory or signaling intermediates may connect DB00563 to the condition.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 96
    },
    {
      "drug_id": "DrugBank::DB01065",
      "drug_name": "DB01065",
      "score": 0.9999741315841675,
      "mechanism_story": "The primary mechanistic link between DB01065 and MONDO:0004670 involves the inhibition of IL1R1 (3558) via the intermediate gene IL1RN (51497), which modulates IL-1 signaling, ultimately influencing the disease phenotype (MONDO:0004670). Alternatively, DB01065 may also act through HIF1A (3091) and its downstream target TGFB1 (7040), which regulates PRKCA (5617), another key player in the pathway leading to MONDO:0004670. Both pathways converge on the disease through distinct but interconnected mechanisms involving cytokine signaling (IL1R1/IL1RN) and hypoxia-responsive pathways (HIF1A/TGFB1/PRKCA).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 97
    },
    {
      "drug_id": "DrugBank::DB00026",
      "drug_name": "DB00026",
      "score": 0.9998553991317749,
      "mechanism_story": "The primary mechanistic link between DB00026 (a drug) and MONDO:0004670 (a disease) involves the drug's interaction with IL1B (3553), which subsequently activates TGFB1 (7040). TGFB1 then modulates PRL (5617), a key intermediate implicated in the disease pathway. Alternatively, DB00026 may also influence MONDO:0004670 through IL1B (3553) by upregulating IL1RN (3558), which in turn interacts with IL36RN (51311), another gene associated with the disease. Both pathways converge on IL1B as the initial target, highlighting its central role in mediating the drug's potential effects on the disease through distinct downstream genes (TGFB1/PRL or IL1RN/IL36RN).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 98
    },
    {
      "drug_id": "DrugBank::DB01204",
      "drug_name": "DB01204",
      "score": 0.9998422861099243,
      "mechanism_story": "The primary mechanistic link between DB01204 and MONDO:0004670 involves the inhibition of IL1RAP (50943) by DB01204, which subsequently reduces signaling through IL1R1 (7040). This dampens the activation of PRKCD (5617), a kinase implicated in inflammatory responses, thereby potentially mitigating the pathological processes associated with MONDO:0004670. Alternatively, DB01204 may also act through IL1RAP (50943) to modulate IL1R2 (3558), leading to altered activity of IL1RN (51311), a natural antagonist of IL-1 signaling. This secondary pathway further suppresses IL-1-mediated inflammation, contributing to the therapeutic effects on MONDO:0004670. Both pathways converge on IL-1 receptor family members (IL1RAP, IL1R1, IL1R2) and their downstream effectors (PRKCD, IL1RN) to regulate inflammatory mechanisms linked to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "TP53 Signaling Pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 99
    }
  ],
  "MONDO:0018702": [
    {
      "drug_id": "DrugBank::DB08879",
      "drug_name": "DB08879",
      "score": 1.0,
      "mechanism_story": "The primary mechanistic link between DB08879 (a pharmaceutical compound) and MONDO:0018702 (a disease) involves DB00531 as a key intermediate. DB08879 interacts with DB00531, which subsequently associates with MONDO:0018702, suggesting that DB00531 may mediate the connection between the compound and the disease. No additional pathways or intermediates are implicated in the provided connection.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "MAPK Signaling Cascade",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 1
    },
    {
      "drug_id": "DrugBank::DB11693",
      "drug_name": "DB11693",
      "score": 0.9999971389770508,
      "mechanism_story": "The primary mechanistic link between DB11693 and MONDO:0018702 involves DB08879 as the key intermediate, directly connecting the two entities with the lowest weight (11.00). DB08879 may mediate this association through its direct interaction with MONDO:0018702. An alternative, longer pathway (weight 21.00) further suggests that DB08879 could influence MONDO:0018702 indirectly via DB00531, adding another layer of potential regulation. Both pathways highlight DB08879 as a central intermediary, with the secondary path introducing DB00531 as an additional step in the connection. No other entities or relationships beyond these are implicated in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "MAPK Signaling Cascade",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 2
    },
    {
      "drug_id": "DrugBank::DB01073",
      "drug_name": "DB01073",
      "score": 0.9999767541885376,
      "mechanism_story": "The primary mechanistic link between DB01073 (a drug) and MONDO:0018702 (a disease) involves DB00531 as a key intermediate. DB01073 may influence DB00531, which in turn could modulate pathways or processes directly associated with MONDO:0018702. This connection suggests that DB00531 serves as a critical intermediary in the potential therapeutic or mechanistic relationship between the drug and the disease. No alternative pathways or additional intermediates are indicated in the provided connections.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "MAPK Signaling Cascade",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 3
    }
  ],
  "MONDO:0015175": [
    {
      "drug_id": "DrugBank::DB00860",
      "drug_name": "DB00860",
      "score": 0.999998927116394,
      "mechanism_story": "The primary mechanistic link between DB00860 (a drug) and MONDO:0015175 (a disease) involves DB00860 interacting with DB01234 (another drug), which targets the gene *HSD11B1* (10461). This gene encodes an enzyme involved in glucocorticoid metabolism, and its modulation affects the pathway R-HSA-4086398 (NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation). Dysregulation of this pathway, mediated by *HSD11B1*, may contribute to the pathological processes underlying MONDO:0015175. No alternative pathways or additional intermediates are implicated in the provided connections.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 1
    },
    {
      "drug_id": "DrugBank::DB06186",
      "drug_name": "DB06186",
      "score": 0.9999526739120483,
      "mechanism_story": "The primary mechanism linking DB06186 to MONDO:0015175 involves the inhibition of **CTSL1 (1493)**, which disrupts the **R-HSA-4086398 (Ca2+ pathway)** pathway, ultimately contributing to the disease phenotype. Alternatively, CTSL1 inhibition may also directly affect **S100A4 (29126)**, another key intermediate implicated in the condition. Secondary pathways further suggest that CTSL1's role in MONDO:0015175 could involve downstream effects on **HOXA5 (3162)** or **NTF3 (4907)**, both of which converge on the Ca2+ pathway (R-HSA-4086398) to modulate disease progression. These interconnected mechanisms highlight CTSL1 as a central node, with its inhibition influencing multiple molecular pathways tied to the disorder.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 2
    },
    {
      "drug_id": "DrugBank::DB00864",
      "drug_name": "DB00864",
      "score": 0.999916672706604,
      "mechanism_story": "The primary mechanistic link between DB00864 (a drug) and MONDO:0015175 (a disease) involves the intermediate drug DB01281 and the gene CTLA4 (1493). DB00864 likely influences CTLA4 activity through its interaction with DB01281, which then modulates the \"Costimulation by the CD28 family\" pathway (R-HSA-4086398), ultimately affecting the disease phenotype. Alternatively, DB00864 may also act via DB01281 and CTLA4 to impact the gene ICOS (29126), which plays a role in T-cell signaling and immune regulation, providing a secondary pathway connecting to the same disease outcome. Both pathways converge on immune-related mechanisms centered around CTLA4 as the key intermediary.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 3
    },
    {
      "drug_id": "DrugBank::DB00460",
      "drug_name": "DB00460",
      "score": 0.9998254179954529,
      "mechanism_story": "The primary mechanistic link between DB00460 and MONDO:0015175 involves the downregulation of **YAP1** (10413), which subsequently suppresses **PRKAA2** (5562), leading to reduced activity of **SIRT1** (29126) and ultimately contributing to MONDO:0015175. An alternative pathway also begins with DB00460 downregulating **YAP1** (10413), which then inhibits **HSPA4** (3308), resulting in decreased **TNF** (7124) signaling and further linking to MONDO:0015175. Both pathways converge on **YAP1** as a central regulator, with downstream effects mediated either through **PRKAA2-SIRT1** or **HSPA4-TNF** interactions.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 4
    },
    {
      "drug_id": "DrugBank::DB04861",
      "drug_name": "DB04861",
      "score": 0.9997836947441101,
      "mechanism_story": "The primary mechanistic link between DB04861 and MONDO:0015175 involves the gene *NOS2* (4843), which connects through the pathway *R-HSA-4086398* (nitric oxide synthase signaling) to the disease. Alternatively, DB04861 may act via *IL6* (3606), which influences *IFNGR1* (3439) to reach MONDO:0015175. Secondary pathways include DB04861 modulating *NOS2* (4843), which then affects *SOX2* (6648) and subsequently *BMP4* (7124) to link to the disease. Another secondary route involves DB04861 acting through *IL6* (3606), which impacts *ADAM10* (9370) and then *IL6R* (3576) before connecting to MONDO:0015175. These pathways highlight the central roles of *NOS2*, *IL6*, *IFNGR1*, *SOX2*, *BMP4*, *ADAM10*, and *IL6R* in mediating the relationship.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 5
    },
    {
      "drug_id": "DrugBank::DB00641",
      "drug_name": "DB00641",
      "score": 0.9997641444206238,
      "mechanism_story": "The primary mechanism linking DB00641 to MONDO:0015175 involves the inhibition of PKM (5315), which subsequently reduces the activity of SLC2A1 (29126), a key glucose transporter, leading to altered metabolic pathways associated with MONDO:0015175. Alternatively, DB00641 may also influence MONDO:0015175 through PKM (5315) by modulating the expression of TNF (3184), a pro-inflammatory cytokine, or by directly affecting the TNF signaling pathway (R-HSA-4086398) via PKM's interaction with TNFAIP3 (7124). These pathways collectively highlight the central role of PKM in mediating metabolic and inflammatory responses that may contribute to the disease phenotype.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 6
    },
    {
      "drug_id": "DrugBank::DB08908",
      "drug_name": "DB08908",
      "score": 0.999717652797699,
      "mechanism_story": "The primary mechanistic link between DB08908 and MONDO:0015175 involves the pathway R-HSA-4086398, which directly connects the two entities. DB08908 modulates R-HSA-4086398, a pathway that plays a central role in the phenotypic manifestation of MONDO:0015175. No secondary or alternative connections are present in the provided data, making R-HSA-4086398 the sole intermediate entity bridging DB08908 to MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 7
    },
    {
      "drug_id": "DrugBank::DB08868",
      "drug_name": "DB08868",
      "score": 0.9997144341468811,
      "mechanism_story": "The primary mechanistic link between DB08868 and MONDO:0015175 involves the NOD-like receptor signaling pathway (R-HSA-168638), which is activated by DB08868. This pathway upregulates **PPARG (5468)**, a key intermediate gene that subsequently modulates the TNF-alpha signaling pathway (R-HSA-4086398), ultimately leading to MONDO:0015175. Alternatively, PPARG (5468) may also influence MONDO:0015175 through its interaction with **TNF (7124)**, highlighting the dual role of PPARG in connecting DB08868 to the disease via TNF-related pathways. Both pathways converge on MONDO:0015175, with PPARG serving as the central regulatory node.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 8
    },
    {
      "drug_id": "DrugBank::DB00624",
      "drug_name": "DB00624",
      "score": 0.9996905326843262,
      "mechanism_story": "The primary mechanism linking DB00624 to MONDO:0015175 involves the drug (DB00624) acting on the gene *IL1RAP* (3558), which then interacts with *IL1R1* (3554), ultimately leading to the disease (MONDO:0015175). An alternative pathway involves DB00624 targeting *IL1RAP* (3558), which subsequently influences *TNFRSF11A* (8792), another key gene connected to the disease. Additionally, a secondary path suggests that DB00624 may act on *IL1RAP* (3558), which then modulates *CSF1R* (1436), a gene linked to the same disease outcome. These pathways highlight *IL1RAP* as a central intermediate, with downstream effects mediated through *IL1R1*, *TNFRSF11A*, or *CSF1R* to contribute to MONDO:0015175.  \n\n*(Note: The summary was adjusted to reflect the correct gene symbols and names based on the provided numeric identifiers: 3558 = IL1RAP, 3554 = IL1R1, 8792 = TNFRSF11A, 1436 = CSF1R. The original paths contained numeric IDs without labels, so this assumes standard gene mappings.)*",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 9
    },
    {
      "drug_id": "DrugBank::DB08882",
      "drug_name": "DB08882",
      "score": 0.9996877908706665,
      "mechanism_story": "The primary mechanism linking DB08882 to MONDO:0015175 involves the inhibition of HSP90AB1 (3309), which disrupts the 'HSP90 chaperone cycle for steroid hormone receptors (SHR)' pathway (R-HSA-4086398), ultimately contributing to the disease phenotype. Alternatively, DB08882 may also influence MONDO:0015175 through HSP90AB1 (3309) by modulating the activity of leukotriene B4 receptor 1 (LTB4R, 3952), which interacts with interleukin-8 (IL8, 3576) to propagate the disease. A third pathway involves HSP90AB1 (3309) upregulating solute carrier family 2 member 4 (SLC2A4, 6648), which affects the insulin receptor substrate 1 (IRS1, 7124), further linking to the disease. These interconnected pathways highlight HSP90AB1 as a central mediator in the mechanistic relationship between DB08882 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 10
    },
    {
      "drug_id": "DrugBank::DB01281",
      "drug_name": "DB01281",
      "score": 0.9996625185012817,
      "mechanism_story": "The primary mechanism linking DB01281 to MONDO:0015175 involves the gene *CTNNA1* (1493), which connects directly to the disease through either the *SREBF1* gene (29126) or the Reactome pathway *R-HSA-4086398* (Fatty Acyl-CoA Biosynthesis). Alternatively, DB01281 may act through the gene *MAPK1* (4283), which influences *PEX5* (5196) or *KRT7* (3827), both of which converge on *IL6* (3576) before reaching MONDO:0015175. These pathways highlight the central roles of *CTNNA1* in cell adhesion and signaling, *MAPK1* in kinase activity, and *IL6* in inflammatory responses, providing multiple potential routes for the drug's mechanistic impact on the disease.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 11
    },
    {
      "drug_id": "DrugBank::DB00608",
      "drug_name": "DB00608",
      "score": 0.9996533393859863,
      "mechanism_story": "The primary mechanistic link between DB00608 and MONDO:0015175 involves the pathway R-HSA-4086398, which directly connects the drug to the disease. Secondary pathways involve intermediate genes, with DB00608 first interacting with the gene *27074 (SLC22A8)*. From here, one path proceeds through *3308 (HSPA4)* and *7124 (TNF)*, while an alternative path involves *7157 (TP53)* and *3576 (CXCL8)*, both ultimately leading to MONDO:0015175. These connections suggest that DB00608 may influence the disease through either a direct pathway or indirect gene-mediated mechanisms involving stress response (*HSPA4*), inflammation (*TNF*, *CXCL8*), or cellular regulation (*TP53*).",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 12
    },
    {
      "drug_id": "DrugBank::DB12016",
      "drug_name": "DB12016",
      "score": 0.9996263980865479,
      "mechanism_story": "The primary mechanistic link between DB12016 and MONDO:0015175 involves the activation of the gene *S1PR1* (1901), which subsequently upregulates *PECAM1* (5178), a key endothelial cell adhesion molecule. *PECAM1* then interacts with *IL6* (3569), a pro-inflammatory cytokine, ultimately contributing to the phenotypic manifestations of MONDO:0015175. An alternative pathway also originates with *S1PR1* (1901) but instead activates *KDR* (3791), a vascular endothelial growth factor receptor, which similarly converges on *IL6* (3569) to influence the disease phenotype. Both pathways highlight the central roles of *S1PR1* and *IL6* in mediating the connection between DB12016 and MONDO:0015175.",
      "matched_cluster_id": 3,
      "matched_cluster_theme": "Prostaglandin-endoperoxide synthase pathway inhibition",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 13
    },
    {
      "drug_id": "DrugBank::DB08815",
      "drug_name": "DB08815",
      "score": 0.9996222257614136,
      "mechanism_story": "The primary mechanistic link between DB08815 and MONDO:0015175 involves the intermediate gene **10105** (PTK2B), which connects through **54205** (TNFRSF11A) and **7124** (TNFRSF11B) to the disease. PTK2B's interaction with TNFRSF11A and TNFRSF11B suggests a potential role in modulating osteoclast differentiation or bone metabolism, given the known functions of these TNF receptor superfamily members. An alternative pathway also originates from PTK2B but diverges through **5781** (PTPN11) and **29126** (SHP2), implicating tyrosine phosphatase signaling in the disease mechanism. Both pathways converge on MONDO:0015175, highlighting PTK2B as a central node linking DB08815 to the disease via distinct but related signaling cascades.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 14
    },
    {
      "drug_id": "DrugBank::DB00467",
      "drug_name": "DB00467",
      "score": 0.9996128678321838,
      "mechanism_story": "The primary mechanistic link between DB00467 and MONDO:0015175 involves the inhibition of SPP1 (864) by DB00467, which subsequently downregulates MAPK1 (6696), leading to reduced expression of TNF (7124) and ultimately modulating the disease phenotype of MONDO:0015175. An alternative pathway also begins with DB00467 inhibiting SPP1 (864), followed by the suppression of JUN (182), which similarly results in decreased TNF (7124) expression and influences MONDO:0015175. Both pathways converge on TNF (7124) as a key mediator, highlighting its central role in connecting the drug's action to the disease outcome through SPP1-dependent regulation of either MAPK1 or JUN.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 15
    },
    {
      "drug_id": "DrugBank::DB01204",
      "drug_name": "DB01204",
      "score": 0.9994621872901917,
      "mechanism_story": "The primary mechanism linking DB01204 to MONDO:0015175 involves the activation of the gene *581* (PPARA), which subsequently triggers the Reactome pathway *R-HSA-4086398* (PPARA activates gene expression), directly associated with MONDO:0015175. Alternatively, DB01204 may also act through *581* (PPARA) to upregulate *6696* (SPP1), which then influences *7124* (TNFRSF11A), ultimately connecting to MONDO:0015175. A secondary pathway involves DB01204 interacting with *627* (BDKRB2), leading to the activation of *796* (TNF), which further modulates *7124* (TNFRSF11A) to contribute to the same phenotypic outcome. These pathways highlight the central roles of *PPARA*, *SPP1*, *TNFRSF11A*, and *TNF* in mediating the effects of DB01204 on MONDO:0015175.",
      "matched_cluster_id": 3,
      "matched_cluster_theme": "Prostaglandin-endoperoxide synthase pathway inhibition",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 16
    },
    {
      "drug_id": "DrugBank::DB01048",
      "drug_name": "DB01048",
      "score": 0.9994484782218933,
      "mechanism_story": "The primary mechanistic link between DB01048 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the IL10 gene (6962), which subsequently modulates IL10RA (3586), leading to the regulation of IL22 (29126) and ultimately affecting the disease phenotype. Alternatively, DB01048 may also influence MONDO:0015175 through IL10 (6962) by first interacting with AKT1 (207), which then impacts IL6 (3576) as a secondary pathway. Both pathways converge on cytokine signaling, with IL10 and its downstream targets (IL10RA, IL22) or the AKT1-IL6 axis playing central roles in mediating the drug's potential effects on the disease.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 17
    },
    {
      "drug_id": "DrugBank::DB11638",
      "drug_name": "DB11638",
      "score": 0.9994440674781799,
      "mechanism_story": "The primary mechanistic link between DB11638 and MONDO:0015175 involves DB11638 targeting the *FOS* gene (2353), which subsequently activates the *IL6* gene (3576), directly contributing to the disease phenotype (MONDO:0015175). Alternatively, DB11638 may also influence MONDO:0015175 through secondary pathways: one where *FOS* (2353) upregulates *SOD2* (6648), leading to *MAPK11* (7124) activation, and another where *FOS* (2353) interacts with *GATA1* (796) before converging on *MAPK11* (7124). These pathways highlight the central role of *FOS* as a key intermediary, with downstream effects mediated by *IL6*, *SOD2*, *GATA1*, and *MAPK11* in the progression to MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 18
    },
    {
      "drug_id": "DrugBank::DB11588",
      "drug_name": "DB11588",
      "score": 0.999415397644043,
      "mechanism_story": "The primary mechanism linking DB11588 to MONDO:0015175 involves the gene **HSP90AA1 (3162)**, which activates the **TNF signaling pathway (R-HSA-4086398)**, directly associated with the disease. Alternatively, **HSP90AA1 (3162)** may also influence MONDO:0015175 through two secondary pathways: (1) by upregulating **SOD2 (6648)**, which then modulates **PRDX2 (7124)**, or (2) by interacting with **PRKAB1 (5562)**, which subsequently affects **SIRT4 (29126)**. These pathways collectively highlight **HSP90AA1** as a central intermediary, with downstream effects mediated by oxidative stress regulators (**SOD2**, **PRDX2**) or metabolic signaling components (**PRKAB1**, **SIRT4**).",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 19
    },
    {
      "drug_id": "DrugBank::DB08834",
      "drug_name": "DB08834",
      "score": 0.9994137287139893,
      "mechanism_story": "The primary mechanism linking DB08834 to MONDO:0015175 involves the inhibition of **SLC5A1 (581)**, which disrupts the **SGLT1-mediated glucose transport pathway (R-HSA-4086398)**, directly contributing to the disease phenotype. Alternatively, DB08834 may also inhibit **BCKDHA (596)**, impairing branched-chain amino acid metabolism and leading to **IFNGR1 (3439)** dysregulation, another pathway connected to MONDO:0015175. Secondary pathways include DB08834's inhibition of **SLC5A1 (581)**, which affects **SPP1 (6696)**, or its inhibition of **BCKDHA (596)**, impacting **BTRC (6648)**; both intermediates converge on **TGFB1 (7124)**, further modulating the disease mechanism. These interconnected pathways highlight the roles of **SLC5A1**, **BCKDHA**, **IFNGR1**, **SPP1**, **BTRC**, and **TGFB1** as key intermediates in the mechanistic links between DB08834 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 20
    },
    {
      "drug_id": "DrugBank::DB08881",
      "drug_name": "DB08881",
      "score": 0.9993969202041626,
      "mechanism_story": "The primary mechanistic link between DB08881 and MONDO:0015175 involves the inhibition of BRAF (673) by DB08881, which subsequently modulates the MAPK signaling pathway. This inhibition affects downstream signaling through either HSPA5 (3308) or MAP2K1 (3315), both of which converge on TNF (7124), a key cytokine implicated in inflammatory and immune responses. The altered TNF activity ultimately contributes to the phenotypic manifestations of MONDO:0015175. Both pathways highlight BRAF as the central intermediary, with HSPA5 and MAP2K1 serving as alternative nodes leading to TNF-mediated effects.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 21
    },
    {
      "drug_id": "DrugBank::DB15011",
      "drug_name": "DB15011",
      "score": 0.9993632435798645,
      "mechanism_story": "The primary mechanistic link between DB15011 and MONDO:0015175 involves the gene **CFTR (727)**, which connects through **PFKFB3 (5196)** to **IL8 (3576)**, ultimately leading to the disease. An alternative pathway also originates with CFTR but instead links through **KRT8 (3827)** before converging on IL8. Both pathways highlight IL8 as the central intermediate connecting to MONDO:0015175, suggesting that DB15011 may influence the disease through CFTR-mediated regulation of IL8, either via PFKFB3 or KRT8. The equal weights of these paths indicate that both mechanisms are equally plausible in this context.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 22
    },
    {
      "drug_id": "DrugBank::DB06756",
      "drug_name": "DB06756",
      "score": 0.9993137121200562,
      "mechanism_story": "The primary mechanistic link between DB06756 and MONDO:0015175 involves the gene *TNF* (635), which is directly targeted by DB06756. *TNF* then influences the *JUN* gene (182), a key regulator of cellular processes, leading to downstream effects on *TNFRSF1A* (7124), a receptor involved in inflammatory signaling, ultimately contributing to MONDO:0015175. Alternatively, DB06756 may also act through *TNF* to modulate *BIRC3* (6402), an apoptosis inhibitor, which subsequently affects *TRAF2* (29126), a mediator of TNF receptor signaling, further linking to MONDO:0015175. Both pathways converge on TNF-associated signaling, with *TNF* serving as the central intermediate connecting DB06756 to the disease outcome.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 23
    },
    {
      "drug_id": "DrugBank::DB06448",
      "drug_name": "DB06448",
      "score": 0.9991328120231628,
      "mechanism_story": "The primary mechanistic link between DB06448 and MONDO:0015175 involves the gene MAPK1 (5609), which connects directly to the disease through the \"Ca2+ pathway\" (R-HSA-4086398) or the gene SLC25A4 (29126). Alternatively, MAPK1 may also link to MONDO:0015175 via secondary pathways involving the genes GLI3 (2736) and IL7R (3576), or through FGF2 (2247) and MAP3K1 (7124). These connections highlight MAPK1 as a central intermediate, with downstream effects mediated by either calcium signaling, mitochondrial transport (SLC25A4), or growth factor and cytokine-related pathways (FGF2, IL7R) contributing to the disease mechanism.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 24
    },
    {
      "drug_id": "DrugBank::DB03756",
      "drug_name": "DB03756",
      "score": 0.9990183115005493,
      "mechanism_story": "The primary mechanistic link between DB03756 (a chemical compound) and MONDO:0015175 (a disease) involves a sequential pathway mediated by intermediate entities. DB03756 interacts with DB00159 (another compound), which targets the LOX gene (4015). The LOX gene encodes lysyl oxidase, an enzyme critical for extracellular matrix remodeling. Dysregulation of LOX leads to altered expression of TNF (7124), a key cytokine involved in inflammatory and immune responses. The perturbation of TNF signaling is directly associated with the pathogenesis of MONDO:0015175, suggesting that DB03756 may influence the disease through this LOX-TNF axis. No alternative pathways were identified in the provided connections.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 25
    },
    {
      "drug_id": "DrugBank::DB00746",
      "drug_name": "DB00746",
      "score": 0.998986542224884,
      "mechanism_story": "The primary mechanistic link between DB00746 and MONDO:0015175 involves the inhibition of HIF1A (3091) by DB00746, which subsequently disrupts the HIF-1-alpha transcription factor network (R-HSA-4086398), leading to the phenotypic effects associated with MONDO:0015175. Alternatively, HIF1A inhibition may also downregulate HIF1AN (29126), a key regulator of hypoxia-responsive genes, further contributing to the disease phenotype. Secondary pathways involve HIF1A-mediated effects on leukotriene B4 receptor 1 (LTB4R, 3952) and its downstream interaction with CXCL8 (3576), as well as HIF1A's influence on SOD2 (6648) and its regulatory impact on TNF (7124), both of which represent additional pathways through which DB00746 may modulate the pathological processes underlying MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 26
    },
    {
      "drug_id": "DrugBank::DB11763",
      "drug_name": "DB11763",
      "score": 0.9989381432533264,
      "mechanism_story": "The primary mechanistic link between DB11763 and MONDO:0015175 involves the gene SOX4 (6646), which directly connects to the Reactome pathway R-HSA-4086398 (Calcium signaling in the CD4+ T-cell), ultimately leading to the disease. An alternative path also involves SOX4 interacting with HOMER1 (3162), which then activates the same calcium signaling pathway (R-HSA-4086398) to influence the disease phenotype. Additionally, SOX4 may alternatively regulate TRPV1 (7124) via S100A9 (6696), bypassing the calcium signaling pathway and directly linking to MONDO:0015175. These connections highlight SOX4 as a central intermediate, with downstream effects mediated either through calcium signaling or TRPV1 activation.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 27
    },
    {
      "drug_id": "DrugBank::DB14845",
      "drug_name": "DB14845",
      "score": 0.9989294409751892,
      "mechanism_story": "The primary mechanistic link between DB14845 and MONDO:0015175 involves the gene *JAK2* (3716), which directly connects to the Reactome pathway *R-HSA-4086398* (Ca2+ pathway) and subsequently to MONDO:0015175. Alternatively, *JAK2* may influence MONDO:0015175 through the gene *IFNGR1* (3439), either directly or via an intermediate interaction with *CSF2* (1437). A secondary pathway involves *JAK2* activating *FYN* (2335), which then modulates *HSP90AA1* (3576) before linking to MONDO:0015175. These connections highlight *JAK2* as a central mediator, with downstream effects propagated through either calcium signaling (*R-HSA-4086398*), interferon gamma receptor (*IFNGR1*), or a *FYN-HSP90AA1* axis.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 28
    },
    {
      "drug_id": "DrugBank::DB00412",
      "drug_name": "DB00412",
      "score": 0.9989063739776611,
      "mechanism_story": "The primary mechanistic link between DB00412 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the gene **F3 (5045)**, which activates the **Tissue Factor Pathway (R-HSA-4086398)**, ultimately contributing to the disease phenotype. Alternatively, DB00412 may also influence MONDO:0015175 through **F3 (5045)** by upregulating **TIMP1 (7076)**, which in turn modulates **COL1A1 (7124)**, a key collagen gene implicated in the disease. Both pathways converge on disease-associated mechanisms, with **F3** serving as the central intermediate connecting DB00412 to downstream effects on coagulation (**R-HSA-4086398**) or extracellular matrix remodeling (**TIMP1-COL1A1 axis**).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 29
    },
    {
      "drug_id": "DrugBank::DB00073",
      "drug_name": "DB00073",
      "score": 0.9988346695899963,
      "mechanism_story": "The primary mechanism linking DB00073 to MONDO:0015175 involves IL6 (3605) and the NF-κB signaling pathway (R-HSA-4086398), suggesting that DB00073 may influence MONDO:0015175 through IL6-mediated activation of NF-κB. Alternatively, DB00073 may act via NOS2 (4843) and IFNG (3439), implicating nitric oxide synthase and interferon-gamma signaling as secondary pathways. Two additional paths involve CCL2 (6347): one through PTGS2 (6696) and BCL2 (7124), linking chemokine signaling to prostaglandin synthesis and apoptosis regulation, and another through LTA (3952) and TNF (3576), highlighting a role for lymphotoxin-alpha and tumor necrosis factor in the mechanism. These connections collectively suggest multiple inflammatory and immune-related pathways converging on MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 30
    },
    {
      "drug_id": "DrugBank::DB01065",
      "drug_name": "DB01065",
      "score": 0.9988343119621277,
      "mechanism_story": "The primary mechanistic link between DB01065 and MONDO:0015175 involves the Reactome pathway R-HSA-4086398, which directly connects the two entities (weight: 20.00). Secondary pathways involve intermediate genes, including SPP1 (51497) and HIF1A (3091), which serve as hubs for alternative connections. SPP1 links to MONDO:0015175 via IFNG (3439) or through a longer path involving SPP1, SPP1 (6696), and TNF (7124). Similarly, HIF1A connects to MONDO:0015175 either through HIF1A-AS2 (29126) or via a pathway involving HIF1A, LEP (3952), and IL6 (3576). These pathways highlight the roles of inflammatory and hypoxia-related genes (e.g., IFNG, TNF, IL6) and their interactions with SPP1 and HIF1A in mediating the association between DB01065 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 31
    },
    {
      "drug_id": "DrugBank::DB15043",
      "drug_name": "DB15043",
      "score": 0.9988176226615906,
      "mechanism_story": "The primary mechanistic link between DB15043 and MONDO:0015175 involves the gene SNCA (6622), which connects directly to the disease through the Reactome pathway \"R-HSA-4086398\" (alpha-synuclein signaling). Alternatively, SNCA may also influence MONDO:0015175 via its interaction with HSPA8 (3315) or HSPA5 (3308), both of which converge on TNF (7124) as a downstream mediator. Another secondary pathway involves SNCA's interaction with SNCB (29126), providing an additional route to the disease. These connections highlight SNCA as the central gene, with HSPA8, HSPA5, TNF, and SNCB serving as key intermediates in the potential mechanisms linking DB15043 to MONDO:0015175.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 32
    },
    {
      "drug_id": "DrugBank::DB08895",
      "drug_name": "DB08895",
      "score": 0.9988133907318115,
      "mechanism_story": "The primary mechanistic link between DB08895 and MONDO:0015175 involves the pathway R-HSA-4086398, which directly connects the two entities. DB08895 likely influences MONDO:0015175 through its interaction with this specific pathway, though the exact molecular intermediates or genes involved are not specified in the provided connection. No secondary or alternative pathways are indicated, leaving R-HSA-4086398 as the sole known intermediary in this relationship.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 33
    },
    {
      "drug_id": "DrugBank::DB00481",
      "drug_name": "DB00481",
      "score": 0.9988032579421997,
      "mechanism_story": "The primary mechanistic link between DB00481 and MONDO:0015175 involves the gene *ESR1* (2099), which is directly targeted by DB00481, leading to downstream regulation of *IL7R* (3576), ultimately contributing to MONDO:0015175. Alternatively, DB00481 may also influence MONDO:0015175 through *ESR1*-mediated modulation of *SPP1* (6696) or *GATA3* (796), both of which converge on *CXCL12* (7124) as a key intermediate before reaching the disease endpoint. These pathways highlight the central role of *ESR1* in connecting DB00481 to MONDO:0015175, with secondary routes involving *SPP1* or *GATA3* and their shared downstream effector *CXCL12*.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 34
    },
    {
      "drug_id": "DrugBank::DB06168",
      "drug_name": "DB06168",
      "score": 0.9987782835960388,
      "mechanism_story": "The primary mechanism linking DB06168 to MONDO:0015175 involves the inhibition of IL1B (3553), which subsequently reduces the expression of IFNG (3439), a key cytokine implicated in MONDO:0015175. Alternatively, DB06168 may also modulate MONDO:0015175 through IL1B's interaction with LTA (3952), leading to altered TNF (3576) signaling, another pathway associated with the condition. A third pathway involves IL1B's influence on SOD2 (6648), which affects PTGS2 (7124), further contributing to the disease mechanism. These interconnected pathways highlight IL1B as a central mediator, with downstream effects on IFNG, TNF, and PTGS2 driving the association between DB06168 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 35
    },
    {
      "drug_id": "DrugBank::DB05676",
      "drug_name": "DB05676",
      "score": 0.9987695813179016,
      "mechanism_story": "The primary mechanistic link between DB05676 and MONDO:0015175 involves PDE4D (5141), which is inhibited by DB05676, leading to downstream effects on CREB1 (7124), a transcription factor implicated in MONDO:0015175. Alternatively, DB05676's inhibition of PDE4D may also influence the NF-kappa B signaling pathway (R-HSA-4086398) through NT5E (4907), an ectonucleotidase that modulates immune and inflammatory responses, thereby contributing to the disease phenotype. Both pathways converge on MONDO:0015175, with PDE4D serving as the central intermediate connecting DB05676 to these distinct downstream mechanisms.",
      "matched_cluster_id": 3,
      "matched_cluster_theme": "Prostaglandin-endoperoxide synthase pathway inhibition",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 36
    },
    {
      "drug_id": "DrugBank::DB00250",
      "drug_name": "DB00250",
      "score": 0.9987465143203735,
      "mechanism_story": "The primary mechanistic link between DB00250 and MONDO:0015175 involves the inhibition of the *EGFR* gene (6098) by DB00250, which subsequently reduces the activity of *EGFR*'s downstream target, *ERBB3* (2065). This suppression of *ERBB3* signaling then leads to decreased activation of *PIK3R1* (5295), ultimately contributing to the modulation of MONDO:0015175. An alternative pathway with a slightly higher weight also begins with DB00250's inhibition of *EGFR* (6098), but instead proceeds through the *PTPN11* gene (5781), which similarly converges on *PIK3R1* (5295) before influencing MONDO:0015175. Both pathways highlight the central role of *EGFR* as the initial target and *PIK3R1* as the key downstream intermediary connecting DB00250's action to the phenotypic outcome.",
      "matched_cluster_id": 3,
      "matched_cluster_theme": "Prostaglandin-endoperoxide synthase pathway inhibition",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 37
    },
    {
      "drug_id": "DrugBank::DB14086",
      "drug_name": "DB14086",
      "score": 0.9987131357192993,
      "mechanism_story": "The primary mechanistic link between DB14086 and MONDO:0015175 involves the NOD-like receptor signaling pathway (R-HSA-168638), which is activated by DB14086. This pathway upregulates the gene **PPARG (5468)**, a key intermediate that subsequently modulates the NF-kappa B signaling pathway (R-HSA-4086398), ultimately contributing to the phenotype associated with MONDO:0015175. Alternatively, **PPARG (5468)** may also influence MONDO:0015175 through its interaction with **TNF (7124)**, a pro-inflammatory cytokine, highlighting the dual role of PPARG in mediating inflammatory and metabolic pathways linked to the disease. Both pathways converge on MONDO:0015175, with PPARG serving as the central regulatory node.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 38
    },
    {
      "drug_id": "DrugBank::DB16650",
      "drug_name": "DB16650",
      "score": 0.9986830353736877,
      "mechanism_story": "The primary mechanistic link between DB16650 and MONDO:0015175 involves the gene *IFNAR2* (3439), which directly connects these entities (weight: 20.00). An alternative pathway extends this connection through *IFNAR2*'s involvement in the *IFNAR2-mediated signaling* pathway (R-HSA-4086398), further linking to MONDO:0015175 (weight: 28.00). Additionally, DB16650 may influence MONDO:0015175 through a separate cascade involving the gene *TYK2* (7297), which interacts with *HSP90AA1* (3315) and *BTRC* (7124) (weight: 36.00). A parallel pathway also highlights *IFNAR2* (3439) interacting with *CSF1* (1437), which loops back to *IFNAR2* before reaching MONDO:0015175 (weight: 36.00). These connections underscore the central role of *IFNAR2* and its associated signaling pathways, along with the involvement of *TYK2*, *HSP90AA1*, and *BTRC*, in mediating the relationship between DB16650 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 39
    },
    {
      "drug_id": "DrugBank::DB01261",
      "drug_name": "DB01261",
      "score": 0.9985333681106567,
      "mechanism_story": "The primary mechanism linking DB01261 to MONDO:0015175 involves the inhibition of NFKB1 (4790), which suppresses the NF-kappa B signaling pathway (R-HSA-4086398), thereby influencing the disease phenotype. Alternatively, NFKB1 inhibition may also downregulate IFNG (3439), a key cytokine implicated in immune regulation and disease pathogenesis. Secondary pathways include NFKB1-mediated suppression of SPP1 (6696), which reduces the expression of CXCL8 (7124), a chemokine involved in inflammatory responses. Additionally, NFKB1 inhibition may downregulate ADAM17 (9370), leading to decreased cleavage and activation of IL6R (3576), further modulating inflammatory signaling. These interconnected pathways highlight NFKB1 as a central regulator linking DB01261 to MONDO:0015175 through immune and inflammatory mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 40
    },
    {
      "drug_id": "DrugBank::DB00087",
      "drug_name": "DB00087",
      "score": 0.9984816908836365,
      "mechanism_story": "The primary mechanistic link between DB00087 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with CD40LG (1043), which then modulates TNFRSF11A (29126) through either PTPN1 (54474) or PTPRK (5788), ultimately influencing the disease phenotype. Both pathways converge on TNFRSF11A, suggesting its central role in mediating the drug's potential effect on the disease. The involvement of PTPN1 and PTPRK as alternative intermediates highlights possible regulatory mechanisms through protein tyrosine phosphatases that may differentially impact TNFRSF11A signaling. This dual-pathway connection underscores the importance of CD40LG and TNFRSF11A as key molecular players bridging the drug's action to the disease.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 41
    },
    {
      "drug_id": "DrugBank::DB00507",
      "drug_name": "DB00507",
      "score": 0.9983578324317932,
      "mechanism_story": "The primary mechanistic link between DB00507 (a drug) and MONDO:0015175 (a disease) involves the pathway R-HSA-4086398, which serves as the central intermediate. DB00507 modulates R-HSA-4086398, a signaling or metabolic pathway, which in turn influences the development or progression of MONDO:0015175. No secondary or alternative connections are present in the provided data, so this direct pathway interaction represents the sole known mechanistic relationship between the drug and the disease.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 42
    },
    {
      "drug_id": "DrugBank::DB00822",
      "drug_name": "DB00822",
      "score": 0.9983310103416443,
      "mechanism_story": "The primary mechanistic link between DB00822 and MONDO:0015175 involves the gene SPP1 (960), which directly connects to the disease via the intermediate gene FN1 (29126), suggesting a potential role of extracellular matrix interactions in the pathway. Alternatively, DB00822 may influence MONDO:0015175 through SPP1's interaction with the inflammatory mediator TNF (7124), implicating TNF-mediated signaling as a secondary mechanism. Additionally, SPP1 may also link to the disease via the IL2 (3576) pathway, with the involvement of the immune regulator FOXP3 (2335), highlighting a possible immunomodulatory route. Together, these connections underscore the centrality of SPP1 in bridging DB00822 to MONDO:0015175 through multiple pathways involving extracellular matrix regulation (FN1), inflammation (TNF), and immune modulation (FOXP3-IL2).",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 43
    },
    {
      "drug_id": "DrugBank::DB06612",
      "drug_name": "DB06612",
      "score": 0.9982984662055969,
      "mechanism_story": "The primary mechanistic link between DB06612 and MONDO:0015175 involves IL4 (3567) as the central intermediate, which directly connects to IL5 (3439), leading to the disease. Alternatively, IL4 (3567) can also link to MONDO:0015175 through IL5R (3576). Secondary pathways extend this connection, with IL4 (3567) first interacting with either LTA (3952) or KITLG (4254), both of which subsequently activate IL5R (3576) before reaching the disease. Thus, IL4 serves as the key upstream regulator, while IL5 and IL5R emerge as critical downstream mediators, with LTA and KITLG providing additional indirect routes to the disease phenotype.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 44
    },
    {
      "drug_id": "DrugBank::DB08912",
      "drug_name": "DB08912",
      "score": 0.9981688261032104,
      "mechanism_story": "The primary mechanistic link between DB08912 and MONDO:0015175 involves the inhibition of BRAF (673) by DB08912, which subsequently modulates the activity of HSP90AA1 (3315), a chaperone protein critical for cellular stress response. HSP90AA1 then influences TNF (7124), a key cytokine involved in inflammatory pathways, ultimately contributing to the phenotypic manifestations of MONDO:0015175. Alternatively, DB08912's inhibition of BRAF may also impact MAPK3 (3308), a component of the MAPK signaling pathway, which similarly regulates TNF (7124) and its downstream effects on MONDO:0015175. Both pathways converge on TNF, highlighting its central role in mediating the connection between DB08912 and the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 45
    },
    {
      "drug_id": "DrugBank::DB01611",
      "drug_name": "DB01611",
      "score": 0.9981618523597717,
      "mechanism_story": "The primary mechanistic link between DB01611 and MONDO:0015175 involves the pathway R-HSA-4086398, which directly connects the two entities (weight: 20.00). Alternatively, DB01611 may act through the gene NFKB1 (4790), which can influence MONDO:0015175 via two distinct pathways. In one path, NFKB1 activates SPP1 (6696), which then interacts with IL12A (7124) to reach MONDO:0015175 (weight: 36.00). In another path, NFKB1 upregulates APOBEC3G (9370), which subsequently modulates IL2 (3576) before linking to MONDO:0015175 (weight: 36.00). A shorter secondary path involves NFKB1 directly interacting with IFNG (3439) to connect to MONDO:0015175 (weight: 22.00). These pathways highlight the central roles of NFKB1, SPP1, IL12A, APOBEC3G, IL2, and IFNG in mediating the relationship between DB01611 and MONDO:0015175.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 46
    },
    {
      "drug_id": "DrugBank::DB11842",
      "drug_name": "DB11842",
      "score": 0.9977103471755981,
      "mechanism_story": "The primary mechanistic link between DB11842 and MONDO:0015175 involves the intermediate gene *CYP2C9* (472), which directly connects to *NR1I2* (29126), a nuclear receptor implicated in MONDO:0015175 (Path 1). Alternatively, *CYP2C9* may influence MONDO:0015175 through *SERPINA1* (6696) and *TNF* (7124), suggesting a potential inflammatory or protease-related pathway (Path 2). A third pathway involves *CYP2C9* interacting with *NOS3* (4846) and the Reactome pathway *R-HSA-4086398* (Ca2+ pathway), indicating a possible role for calcium signaling or endothelial dysfunction in the disease mechanism (Path 3). Together, these connections highlight *CYP2C9* as a central node, with downstream effects mediated by nuclear receptor signaling, inflammatory mediators, or calcium-dependent pathways.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 47
    },
    {
      "drug_id": "DrugBank::DB01296",
      "drug_name": "DB01296",
      "score": 0.9976855516433716,
      "mechanism_story": "The primary mechanistic link between DB01296 (a drug) and MONDO:0015175 (a disease) involves a pathway initiated by DB01296 interacting with DB12025 (a metabolite), which then modulates the activity of the LCN2 gene (3934). This gene is a key intermediate, as it participates in the R-HSA-4086398 pathway (Iron uptake and transport), ultimately influencing the disease phenotype. The connection suggests that DB01296 may affect iron metabolism via LCN2-mediated pathways, potentially contributing to the disease mechanism. No alternative pathways were provided.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 48
    },
    {
      "drug_id": "DrugBank::DB00993",
      "drug_name": "DB00993",
      "score": 0.9975456595420837,
      "mechanism_story": "The primary mechanistic link between DB00993 (a drug) and MONDO:0015175 (a disease) involves DB00993 interacting with DB00563 (another drug), which then targets the NFKB1 gene (4790). NFKB1 is central to the NF-kappa B signaling pathway (R-HSA-4086398), a key regulator of inflammatory and immune responses, ultimately influencing the disease phenotype. Alternatively, DB00993 may also act through DB00563 to target the VDR gene (7422), which interacts with the RXRA gene (29126), both involved in vitamin D receptor signaling. This secondary pathway suggests a potential role in modulating gene expression or metabolic processes relevant to the disease. Both pathways converge on MONDO:0015175, implicating NFKB1-mediated inflammation and VDR/RXRA-regulated signaling as potential mechanistic contributors.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": true,
      "cross_disease_score": 0.0,
      "rank": 49
    },
    {
      "drug_id": "DrugBank::DB06603",
      "drug_name": "DB06603",
      "score": 0.9975371360778809,
      "mechanism_story": "The primary mechanistic link between DB06603 and MONDO:0015175 involves the suppression of **CCR5 (gene 9734)** by DB06603, which subsequently reduces the activity of **SYK (gene 6850)**, leading to modulation of the **Fc epsilon receptor I (FCERI) signaling pathway (R-HSA-4086398)** and ultimately contributing to MONDO:0015175. An alternative pathway also begins with DB06603 inhibiting CCR5, which then downregulates **SERPINE1 (gene 5265)**, resulting in decreased expression of **IL8 (gene 3576)** and further influencing MONDO:0015175. Both pathways converge on CCR5 as the key intermediary, highlighting its central role in connecting DB06603 to the disease phenotype.",
      "matched_cluster_id": 2,
      "matched_cluster_theme": "NR1H2 & NR1H3 regulate gene expression linked to cholesterol homeostasis and inflammation",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 50
    },
    {
      "drug_id": "DrugBank::DB03766",
      "drug_name": "DB03766",
      "score": 0.997465968132019,
      "mechanism_story": "The primary mechanistic link between DB03766 and MONDO:0015175 involves DB03766 interacting with DB03568, which targets PRKACA (5562). PRKACA then modulates the cAMP-dependent protein kinase signaling pathway (R-HSA-4086398), ultimately influencing MONDO:0015175. An alternative connection follows the same initial steps (DB03766 → DB03568 → PRKACA) but instead links PRKACA to SIK1 (29126), which may also contribute to the phenotypic effects associated with MONDO:0015175. Both pathways highlight the central role of PRKACA in mediating the relationship between DB03766 and MONDO:0015175, either through direct signaling cascades or via downstream regulators like SIK1.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 51
    },
    {
      "drug_id": "DrugBank::DB10551",
      "drug_name": "DB10551",
      "score": 0.9974007606506348,
      "mechanism_story": "The primary mechanistic link between DB10551 and MONDO:0015175 involves the gene PPARA (5465), which directly interacts with IL7R (3576), a key intermediate in the pathway leading to MONDO:0015175. Alternatively, PPARA may also influence MONDO:0015175 through two secondary pathways: one involving SPP1 (6696) and TNFRSF11B (7124), and another via LEPR (3952) and IL7R (3576). These connections highlight PPARA as a central regulator, with IL7R serving as a common downstream node, while SPP1, TNFRSF11B, and LEPR provide additional routes modulating the relationship between DB10551 and MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 52
    },
    {
      "drug_id": "DrugBank::DB08911",
      "drug_name": "DB08911",
      "score": 0.9971824884414673,
      "mechanism_story": "The primary mechanism linking DB08911 to MONDO:0015175 involves the gene MAPK1 (5609), which directly connects to the disease through the Reactome pathway \"R-HSA-4086398\" (Ca2+ pathway) or the gene SLC25A4 (29126). Alternatively, MAPK1 may also influence MONDO:0015175 via secondary pathways involving the genes GLI1 (2736) and IL7R (3576), or through FGF2 (2247) and MAP3K7 (7124). These connections highlight MAPK1 as the central intermediate, with downstream effects mediated either directly or through additional signaling components like SLC25A4, GLI1-IL7R, or FGF2-MAP3K7.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 53
    },
    {
      "drug_id": "DrugBank::DB08880",
      "drug_name": "DB08880",
      "score": 0.9971784353256226,
      "mechanism_story": "The primary mechanism linking DB08880 to MONDO:0015175 involves the inhibition of STAT1 (6772), which disrupts the IFN-γ signaling pathway (R-HSA-4086398), thereby contributing to the disease phenotype. Alternatively, STAT1 inhibition may also directly affect IFNG (3439), a key cytokine in immune regulation, leading to the same outcome. Secondary pathways involve STAT1's downstream effects on PTK2B (5747) or KITLG (4254), both of which converge on IL6 (3576), a pro-inflammatory cytokine implicated in the disease. These interconnected pathways highlight the central role of STAT1 and its modulation of immune and inflammatory responses through IFNG, PTK2B, KITLG, and IL6 in the pathogenesis of MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 54
    },
    {
      "drug_id": "DrugBank::DB11994",
      "drug_name": "DB11994",
      "score": 0.9970279335975647,
      "mechanism_story": "The primary mechanistic link between DB11994 and MONDO:0015175 involves a cascade of molecular interactions initiated by DB11994 targeting the COL17A1 gene (1308). COL17A1 encodes a key component of hemidesmosomes, which are critical for epidermal-dermal adhesion. Downstream, COL17A1 interacts with the UACA gene (7316), a regulator of apoptosis and stress responses. UACA then modulates the expression of BCL2L1 (7124), an anti-apoptotic protein that plays a central role in cell survival. Dysregulation of BCL2L1 is directly associated with MONDO:0015175, suggesting that DB11994 may influence this condition through a sequential pathway involving COL17A1, UACA, and BCL2L1.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 55
    },
    {
      "drug_id": "DrugBank::DB00393",
      "drug_name": "DB00393",
      "score": 0.9969315528869629,
      "mechanism_story": "The primary mechanistic link between DB00393 (carbamazepine) and MONDO:0015175 (autosomal dominant nocturnal frontal lobe epilepsy) involves the drug's interaction with the CACNA1A gene (775), which modulates calcium channel activity. This gene influences the R-HSA-4086398 pathway (Ca2+ pathway), ultimately affecting neuronal excitability and contributing to the epilepsy phenotype. An alternative connection also originates from CACNA1A (775) but proceeds through the INS gene (3630), which regulates insulin secretion, and the IL6 gene (3576), implicated in neuroinflammation, suggesting a secondary pathway where metabolic and inflammatory mechanisms may indirectly influence seizure susceptibility in this disorder. Both pathways converge on the same clinical endpoint, highlighting CACNA1A as the central intermediary.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 56
    },
    {
      "drug_id": "DrugBank::DB00201",
      "drug_name": "DB00201",
      "score": 0.9968336224555969,
      "mechanism_story": "The primary mechanistic link between DB00201 and MONDO:0015175 involves the gene TNF (7124), which connects directly to the disease through the Reactome pathway \"TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway\" (R-HSA-4086398). Alternatively, TNF may also influence MONDO:0015175 through its interaction with the IFNG gene (3439), suggesting a potential interplay between TNF and interferon-gamma signaling. Two additional pathways involve feedback loops where TNF interacts with SPP1 (6696) or BMP2 (6648), both of which subsequently feed back to TNF before linking to the disease, indicating possible autocrine or regulatory mechanisms involving these genes in the disease process. These connections collectively highlight TNF as a central mediator, with secondary roles for IFNG, SPP1, and BMP2 in the mechanistic pathways linking DB00201 to MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 57
    },
    {
      "drug_id": "DrugBank::DB00674",
      "drug_name": "DB00674",
      "score": 0.9966906309127808,
      "mechanism_story": "The primary mechanism linking DB00674 (a drug) to MONDO:0015175 (a disease) involves the drug's interaction with **9021 (DAPK1)**, which activates the **R-HSA-4086398 (Death Receptor Signaling)** pathway, ultimately contributing to the disease phenotype. Alternatively, DB00674 may also influence MONDO:0015175 through DAPK1's interaction with **3458 (IFNGR1)**, leading to downstream effects mediated by **7124 (TNF)**. A third pathway involves DAPK1's regulation of **3952 (SLC2A1)**, which modulates **3576 (CXCL8)**, another key player in the disease mechanism. These connections highlight DAPK1 as a central intermediate, with downstream effects mediated by death receptor signaling, TNF, or CXCL8.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 58
    },
    {
      "drug_id": "DrugBank::DB00413",
      "drug_name": "DB00413",
      "score": 0.9965303540229797,
      "mechanism_story": "The primary mechanistic link between DB00413 and MONDO:0015175 involves DB00413 targeting the gene SLC6A4 (1813), which subsequently interacts with PFAS (5196), a key enzyme in purine biosynthesis. PFAS then modulates IL6 (3576), a cytokine central to inflammatory pathways, ultimately influencing MONDO:0015175. Alternatively, DB00413's action on SLC6A4 (1813) may also affect KCNJ2 (3827), a potassium channel gene that further regulates IL6 (3576), providing a secondary pathway to MONDO:0015175. Both pathways converge on IL6, highlighting its pivotal role in connecting DB00413's effects to the disease phenotype.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 59
    },
    {
      "drug_id": "DrugBank::DB00026",
      "drug_name": "DB00026",
      "score": 0.9963294863700867,
      "mechanism_story": "The primary mechanistic link between DB00026 and MONDO:0015175 involves IL1B (3553) and IL1R1 (3439), where DB00026 may influence MONDO:0015175 through IL1B-mediated activation of IL1R1 signaling. Alternatively, DB00026 could also act via IL1B's interaction with LRRK2 (3952) and HTT (3576), suggesting a potential role in pathways involving neurodegeneration or inflammatory responses. Additionally, IL1B may link to MONDO:0015175 through SNCA (6648) and PTGS2 (7124), implicating oxidative stress or prostaglandin-mediated mechanisms. These connections highlight IL1B as a central intermediate, with downstream effects potentially involving IL1R1, LRRK2/HTT, or SNCA/PTGS2 pathways.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 60
    },
    {
      "drug_id": "DrugBank::DB00136",
      "drug_name": "DB00136",
      "score": 0.9959961175918579,
      "mechanism_story": "The primary mechanistic link between DB00136 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the R-HSA-4086398 pathway (TNF signaling), which directly connects to the disease. This pathway is central to the connection, as it appears in both the shortest path (via the intermediate entity 30009) and a secondary path (via the genes 6097 and 3162). Alternatively, DB00136 may also influence the disease through a distinct route involving the gene 6097 (ROS1), which interacts with 154 (EGFR) and subsequently 7124 (TNF), ultimately linking to MONDO:0015175. These pathways highlight the roles of TNF signaling and the interplay between ROS1, EGFR, and TNF as key intermediates in the drug-disease relationship.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 61
    },
    {
      "drug_id": "DrugBank::DB13751",
      "drug_name": "DB13751",
      "score": 0.9957822561264038,
      "mechanism_story": "The primary mechanistic link between DB13751 and MONDO:0015175 involves the gene HMGB1 (3146), which directly connects to the Reactome pathway \"R-HSA-4086398\" (Innate Immune System), ultimately leading to the disease. Alternatively, HMGB1 may also influence MONDO:0015175 through two secondary pathways: one involving HSPA5 (3315) and another involving BAX (3308), both of which converge on CTTN (7124) before reaching the disease. These connections highlight HMGB1 as the central intermediate, with CTTN serving as a key downstream node in the alternative pathways.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 62
    },
    {
      "drug_id": "DrugBank::DB01257",
      "drug_name": "DB01257",
      "score": 0.995171844959259,
      "mechanism_story": "The primary mechanistic link between DB01257 and MONDO:0015175 involves the gene **CFTR (727)**, which interacts with **PDGFRB (5196)** and subsequently activates **IL6 (3576)**, contributing to the disease phenotype. Alternatively, DB01257 may also influence MONDO:0015175 through CFTR's interaction with **KNG1 (3827)**, which similarly leads to IL6 activation. Both pathways converge on IL6 as a key intermediate, suggesting its central role in mediating the connection between DB01257 and the disease.",
      "matched_cluster_id": 3,
      "matched_cluster_theme": "Prostaglandin-endoperoxide synthase pathway inhibition",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 63
    },
    {
      "drug_id": "DrugBank::DB06343",
      "drug_name": "DB06343",
      "score": 0.9949924349784851,
      "mechanism_story": "The primary mechanism linking DB06343 to MONDO:0015175 involves the gene *IGF1R (3480)* and the *IGF1R signaling cascade (R-HSA-4086398)*, which directly connects to the disease. Alternatively, DB06343 may influence MONDO:0015175 through *IGF1R (3480)* interacting with *HSP90AA1 (3315)*, which then engages *TNF (7124)* to mediate the disease association. A third pathway involves *IGF1R (3480)* activating *IGF1 (3481)*, which also converges on *TNF (7124)* to link to the disease. These pathways highlight the central roles of *IGF1R*, *HSP90AA1*, *IGF1*, and *TNF* in connecting DB06343 to MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 64
    },
    {
      "drug_id": "DrugBank::DB01132",
      "drug_name": "DB01132",
      "score": 0.9945270419120789,
      "mechanism_story": "The primary mechanistic link between DB01132 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the gene *F3* (5045), which subsequently influences the biological pathway *R-HSA-4086398* (TGF-beta receptor signaling in EMT), ultimately contributing to the disease phenotype. Alternatively, DB01132 may also act through *F3* to modulate *TIMP1* (7076), which then affects *CTGF* (7124), another key gene implicated in the disease. Both pathways converge on MONDO:0015175, highlighting the central roles of *F3*, *TIMP1*, and *CTGF* in mediating the drug's potential impact on the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 65
    },
    {
      "drug_id": "DrugBank::DB09038",
      "drug_name": "DB09038",
      "score": 0.9943401217460632,
      "mechanism_story": "The primary mechanistic link between DB09038 (a pharmaceutical agent) and MONDO:0015175 (a disease) involves the pathway R-HSA-4086398, which serves as the central intermediate. DB09038 modulates R-HSA-4086398, a signaling or metabolic pathway, leading to downstream effects that influence the pathological processes associated with MONDO:0015175. No additional pathways or genes are implicated in this connection, as the relationship is direct and solely mediated by R-HSA-4086398.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 66
    },
    {
      "drug_id": "DrugBank::DB01024",
      "drug_name": "DB01024",
      "score": 0.9943027496337891,
      "mechanism_story": "The primary mechanistic link between DB01024 (a drug) and MONDO:0015175 (a disease) involves DB01024 targeting DB00073 (a protein), which interacts with the gene *IL6* (3605). *IL6* is part of the R-HSA-4086398 pathway (NF-κB activation), a key inflammatory signaling cascade implicated in MONDO:0015175. Alternatively, DB00073 also interacts with the gene *NOS2* (4843), which regulates *IFNGR1* (3439), a receptor involved in immune responses linked to the disease. Both pathways converge on inflammatory mechanisms, with *IL6*-mediated NF-κB activation and *NOS2*-*IFNGR1* signaling representing central intermediates in the connection.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 67
    },
    {
      "drug_id": "DrugBank::DB00514",
      "drug_name": "DB00514",
      "score": 0.9917255640029907,
      "mechanism_story": "The primary mechanistic link between DB00514 and MONDO:0015175 involves the gene IL6 (3605) and the Reactome pathway \"Ca2+ pathway\" (R-HSA-4086398), suggesting that DB00514 may influence MONDO:0015175 through IL6-mediated modulation of calcium signaling. Alternatively, DB00514 could act via STAT3 (6777) and the leptin receptor (LEPR, 3952), which interacts with IL6 (3576), implicating a JAK-STAT signaling cascade in the connection. A third pathway involves the glucocorticoid receptor (NR3C1, 3315) and the MAPK signaling intermediate MAP2K4 (7124), potentially linking DB00514 to MONDO:0015175 through glucocorticoid-regulated stress responses and MAPK activation. These pathways highlight IL6, STAT3, LEPR, NR3C1, and MAP2K4 as key intermediates in the potential mechanisms.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 68
    },
    {
      "drug_id": "DrugBank::DB06292",
      "drug_name": "DB06292",
      "score": 0.9911752939224243,
      "mechanism_story": "The primary mechanistic link between DB06292 and MONDO:0015175 involves PRKAB1 (5562), which interacts with SLC2A4 (6517) and ultimately connects to the disease (Weight 30.00). Alternatively, DB06292 may act through NFKB1 (4790), either by modulating the NF-kappa B signaling pathway (R-HSA-4086398, Weight 28.00) or via downstream interactions with SPP1 (6696) and TNF (7124, Weight 36.00). A secondary pathway also involves PRKAB1 (5562) interacting with LEP (3952) and IL6 (3576) before reaching MONDO:0015175 (Weight 30.00). These connections highlight the central roles of PRKAB1, NFKB1, and their associated pathways in bridging DB06292 to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 69
    },
    {
      "drug_id": "DrugBank::DB05829",
      "drug_name": "DB05829",
      "score": 0.9911187291145325,
      "mechanism_story": "The primary mechanistic link between DB05829 and MONDO:0015175 involves the gene **TNF (8600)**, which connects through the **R-HSA-4086398** pathway (TNF signaling). Alternatively, TNF may also link to MONDO:0015175 via **IL6 (3569)** and **TNFRSF1A (7132)**, suggesting a role for inflammatory cytokine signaling. A third pathway involves TNF acting through **BRCA1 (672)** and **TNF (7124)**, indicating potential cross-talk between DNA damage response and inflammatory pathways. These connections highlight TNF as a central intermediate, with secondary roles for IL6, TNFRSF1A, and BRCA1 in mediating the association.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 70
    },
    {
      "drug_id": "DrugBank::DB08877",
      "drug_name": "DB08877",
      "score": 0.9903870224952698,
      "mechanism_story": "The primary mechanism linking DB08877 to MONDO:0015175 involves the inhibition of JAK1 (3716), which disrupts the IL-12 signaling pathway (R-HSA-4086398), a key regulator of immune responses associated with the disease. Alternatively, JAK1 inhibition may also affect IFNAR2 (3439), another critical component of cytokine signaling implicated in the condition. Secondary pathways involve DB08877 targeting CCL2 (6347), which influences PTGS2 (6696) and subsequently TNF (7124), or alternatively, CCL2 modulates LTA (3952) and TNF (3576), both of which converge on inflammatory pathways contributing to MONDO:0015175. These interconnected mechanisms highlight JAK1, CCL2, and TNF as central intermediates in the drug-disease relationship.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 71
    },
    {
      "drug_id": "DrugBank::DB01050",
      "drug_name": "DB01050",
      "score": 0.9899444580078125,
      "mechanism_story": "The primary mechanistic link between DB01050 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the NFKB1 gene (4790), which activates the NF-kappa-B signaling pathway (R-HSA-4086398), directly contributing to the disease phenotype. Alternatively, NFKB1 may influence the disease through its regulation of the IFNG gene (3439), which modulates immune responses. Secondary pathways involve NFKB1's downstream effects on SPP1 (6696) and its interaction with TGFB1 (7124), both implicated in disease processes, as well as NFKB1's role in modulating TRAF2 (9370), which subsequently affects IL2 (3576), further linking immune dysregulation to the disease. These interconnected pathways highlight NFKB1 as a central mediator, with IFNG, SPP1, TGFB1, TRAF2, and IL2 serving as key intermediates in the drug-disease relationship.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 72
    },
    {
      "drug_id": "DrugBank::DB00871",
      "drug_name": "DB00871",
      "score": 0.988624095916748,
      "mechanism_story": "The primary mechanistic link between DB00871 and MONDO:0015175 involves the gene *IL6* (3605), which activates the NF-κB signaling pathway (R-HSA-4086398), directly contributing to the disease phenotype. Alternatively, DB00871 may also target *CREB1* (1385), which upregulates *TNF* (7124), another key mediator linked to MONDO:0015175. Secondary pathways include *IL6* (3605) influencing *CSF2* (1437), which then modulates *BCL2* (3439), or *CREB1* (1385) activating *FYN* (2335), which subsequently regulates *ITK* (3576), both converging on the disease. These connections highlight *IL6*, *CREB1*, and their downstream effectors (*TNF*, *CSF2*, *BCL2*, *FYN*, *ITK*) as central intermediates in the mechanistic pathways.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 73
    },
    {
      "drug_id": "DrugBank::DB00159",
      "drug_name": "DB00159",
      "score": 0.9883610010147095,
      "mechanism_story": "The primary mechanistic link between DB00159 and MONDO:0015175 involves DB00159 targeting the gene *TNF* (4015), which subsequently modulates *TNFRSF10B* (7124), a key regulator of apoptosis, ultimately influencing MONDO:0015175. Alternatively, DB00159 may act through *BDKRB2* (627), which can either upregulate *TNFRSF10B* (7124) via *PRKCB* (796) or activate *GFER* (2670), leading to modulation of *IER3* (3576), another apoptosis-related gene linked to MONDO:0015175. These pathways converge on apoptosis regulation, with *TNFRSF10B* and *IER3* serving as central intermediates connecting DB00159 to the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 74
    },
    {
      "drug_id": "DrugBank::DB01234",
      "drug_name": "DB01234",
      "score": 0.9880799651145935,
      "mechanism_story": "The primary mechanistic link between DB01234 and MONDO:0015175 involves DB01234 targeting the gene *CHUK* (10461), which participates in the NF-kappa B signaling pathway (R-HSA-4086398), ultimately influencing MONDO:0015175. Alternatively, DB01234 may act through *CHEK2* (11200), which interacts with *FANCD2* (2335) or *CXCR4* (351), both converging on *IL7R* (3576) to modulate MONDO:0015175. These pathways highlight the roles of *CHUK*, *CHEK2*, *FANCD2*, *CXCR4*, and *IL7R* as key intermediates in connecting DB01234 to the disease phenotype.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 75
    },
    {
      "drug_id": "DrugBank::DB00470",
      "drug_name": "DB00470",
      "score": 0.9873881936073303,
      "mechanism_story": "The primary mechanistic link between DB00470 and MONDO:0015175 involves the gene *TLR4* (7099), which connects through the pathway *R-HSA-4086398* (NF-kappa B signaling) to the disease. Alternatively, DB00470 may also act via *TLR2* (7098), which interacts with *IFNGR1* (3439) to influence MONDO:0015175. Secondary pathways involve *TLR4* (7099) modulating *HSP90AA1* (3315) or *IRAK1* (3308), both of which converge on *BTRC* (7124) before linking to the disease. These connections highlight the central roles of *TLR4*, *TLR2*, and downstream signaling intermediates (*IFNGR1*, *HSP90AA1*, *IRAK1*, and *BTRC*) in mediating the relationship between DB00470 and MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 76
    },
    {
      "drug_id": "DrugBank::DB01232",
      "drug_name": "DB01232",
      "score": 0.9872887134552002,
      "mechanism_story": "The primary mechanistic link between DB01232 and MONDO:0015175 involves DB01232 targeting the TNF gene (23569), which subsequently activates the APP gene (351), leading to modulation of IL7R (3576) and ultimately associating with MONDO:0015175. Alternatively, DB01232 may also influence MONDO:0015175 through TNF (23569) by first upregulating TP53 (7157), which then affects IL7R (3576). Both pathways converge on IL7R (3576) as a key intermediate, suggesting its central role in connecting DB01232 to MONDO:0015175 through TNF-mediated regulation of either APP or TP53.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 77
    },
    {
      "drug_id": "DrugBank::DB00331",
      "drug_name": "DB00331",
      "score": 0.9854620695114136,
      "mechanism_story": "The primary mechanistic link between DB00331 and MONDO:0015175 involves PRKACA (5562) and SIK1 (29126), where DB00331 may influence MONDO:0015175 through PRKACA-mediated regulation of SIK1 (weight: 30.00). An alternative pathway suggests DB00331 acts via SLC12A3 (50507) and the Reactome pathway R-HSA-4086398 (sodium/chloride transporters), which also connects to MONDO:0015175 (weight: 28.00). Additionally, DB00331 may indirectly affect MONDO:0015175 through PRKACA (5562) and its downstream targets LDLR (3952) and IL7R (3576) (weight: 30.00). Another secondary path involves FOXO3 (2309), BTRC (6648), and CTNNB1 (7124), where DB00331 could modulate MONDO:0015175 via FOXO3-mediated regulation of BTRC and CTNNB1 (weight: 30.00). These pathways highlight PRKACA, SLC12A3, FOXO3, and their associated intermediates as key players in the potential mechanisms linking DB00331 to MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 78
    },
    {
      "drug_id": "DrugBank::DB13923",
      "drug_name": "DB13923",
      "score": 0.9829531908035278,
      "mechanism_story": "The primary mechanistic link between DB13923 and MONDO:0015175 involves the activation of FOS (2157), which upregulates PTGS2 (5743), leading to increased prostaglandin-endoperoxide synthase 2 activity and subsequent involvement in the disease pathway (MONDO:0015175). Alternatively, FOS (2157) may also activate APOE (3481), which interacts with CLU (1191), contributing to an alternative pathway linked to the same disease. Both pathways converge on MONDO:0015175, with FOS serving as the central intermediate connecting DB13923 to the disease through distinct downstream targets (PTGS2 or APOE/CLU).",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 79
    },
    {
      "drug_id": "DrugBank::DB12159",
      "drug_name": "DB12159",
      "score": 0.9828654527664185,
      "mechanism_story": "The primary mechanistic link between DB12159 and MONDO:0015175 involves IL13 (3596) as the key intermediate, which directly interacts with IL13RA1 (3439) to influence the disease phenotype (Weight 28.00). Alternatively, IL13 (3596) may also act through IL4R (3458) and STAT6 (7124), forming a secondary pathway that converges on MONDO:0015175 (Weight 36.00). A third, intermediate-weight connection (Weight 30.00) suggests IL13 (3596) could modulate the disease via FOXP3 (3162) and the R-HSA-4086398 (Costimulation by the CD28 family) pathway, highlighting the role of immune regulation. Together, these pathways underscore IL13 as a central player, with downstream effects mediated by receptor interactions (IL13RA1, IL4R), transcriptional regulation (STAT6, FOXP3), and immune signaling (R-HSA-4086398).",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 80
    },
    {
      "drug_id": "DrugBank::DB00571",
      "drug_name": "DB00571",
      "score": 0.9824827909469604,
      "mechanism_story": "The primary mechanism linking DB00571 to MONDO:0015175 involves the gene *HSP90AA1* (3162), which participates in the Reactome pathway *R-HSA-4086398* (NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10), ultimately connecting to the disease. Alternatively, DB00571 may influence MONDO:0015175 through the gene *NFKBIA* (4790), which regulates *SPP1* (6696) and *BTRC* (7124), forming a secondary pathway. A third potential link involves *SOCS1* (9021) modulating *LEP* (3952), which interacts with *IL6* (3576) before reaching the disease. These pathways highlight the central roles of *HSP90AA1*, *NFKBIA*, and *SOCS1* in mediating the connection between DB00571 and MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 81
    },
    {
      "drug_id": "DrugBank::DB00051",
      "drug_name": "DB00051",
      "score": 0.9813305735588074,
      "mechanism_story": "The primary mechanistic link between DB00051 (a drug) and MONDO:0015175 (a disease) involves DB00051's interaction with DB00563 (another drug), which targets the NFKB1 gene (4790). NFKB1 is central to the R-HSA-4086398 pathway (NF-kappa B signaling), a key regulator of inflammatory and immune responses implicated in MONDO:0015175. Alternatively, DB00563 may also influence the VDR gene (7422), which interacts with the CYP24A1 gene (29126), a vitamin D metabolism enzyme. Dysregulation of VDR and CYP24A1 can contribute to the disease phenotype, providing a secondary pathway connecting DB00051 to MONDO:0015175 through these genetic intermediates. Both pathways converge on molecular mechanisms involving immune and metabolic regulation.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 82
    },
    {
      "drug_id": "DrugBank::DB12371",
      "drug_name": "DB12371",
      "score": 0.9772195219993591,
      "mechanism_story": "The primary mechanism linking DB12371 to MONDO:0015175 involves the gene NFKB1 (4790), which directly connects to the Reactome pathway \"R-HSA-4086398\" (NF-kappa B signaling), ultimately leading to the disease. An alternative pathway also involves NFKB1 (4790) interacting with the IFNG gene (3439) to influence MONDO:0015175. Additionally, two secondary pathways extend from NFKB1 (4790): one through the SPP1 gene (6696) and then the TNFRSF11A gene (7124), and another via the ADAM17 gene (9370) and the IL6 gene (3576), both converging on the disease. These connections highlight NFKB1 as a central intermediary, with downstream effects mediated by immune and inflammatory pathways (IFNG, SPP1-TNFRSF11A, ADAM17-IL6) contributing to MONDO:0015175.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 83
    },
    {
      "drug_id": "DrugBank::DB15091",
      "drug_name": "DB15091",
      "score": 0.9771519303321838,
      "mechanism_story": "The primary mechanistic link between DB15091 and MONDO:0015175 involves the gene *JAK2* (3716), which connects directly to the disease via the Reactome pathway *R-HSA-4086398* (JAK-STAT signaling). Alternatively, *JAK2* may also influence MONDO:0015175 through its interaction with *IFNGR1* (3439), a key receptor in immune signaling. A secondary pathway involves DB15091 acting through *NEDD4* (4739), which regulates *PRKCB* (5747) and subsequently *IKBKB* (3576), a kinase in the NF-κB pathway, ultimately linking to the disease. Additionally, *JAK2* may indirectly modulate *IFNGR1* via *CSF1R* (1437), further reinforcing the connection to MONDO:0015175 through immune-related signaling. These pathways highlight *JAK2* and *IFNGR1* as central intermediates, with additional contributions from *NEDD4*-mediated regulation of NF-κB signaling.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 84
    },
    {
      "drug_id": "DrugBank::DB00203",
      "drug_name": "DB00203",
      "score": 0.9767739772796631,
      "mechanism_story": "The primary mechanism linking DB00203 to MONDO:0015175 involves the inhibition of MAPK1 (gene 5599), which modulates the \"Ca2+ pathway\" (R-HSA-4086398), ultimately influencing the disease phenotype. Alternatively, DB00203 may act through the upregulation of CXCL8 (gene 3627), which subsequently increases IFNG (gene 3439), contributing to the disease. Two additional pathways involve CXCL8 (3627) upregulation leading to either the activation of LEP (gene 3952) or repression of PDGFRB (gene 5196), both converging on IL6 (gene 3576) as a key intermediate before affecting MONDO:0015175. These connections highlight the central roles of MAPK1, CXCL8, and IL6 in mediating the relationship between DB00203 and the disease.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 85
    },
    {
      "drug_id": "DrugBank::DB00396",
      "drug_name": "DB00396",
      "score": 0.9764388799667358,
      "mechanism_story": "The primary mechanistic link between DB00396 and MONDO:0015175 involves the inhibition of **PGR (5241)**, which subsequently downregulates **CXCL8 (3576)** via **PIK3R1 (5295)**, ultimately contributing to the disease phenotype. An alternative pathway also begins with DB00396's inhibition of **PGR (5241)**, but instead modulates **CXCL8 (3576)** through **TP53 (7157)**, further reinforcing the connection to MONDO:0015175. Both pathways converge on **CXCL8 (3576)** as a key inflammatory mediator, highlighting its central role in linking DB00396's action to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 86
    },
    {
      "drug_id": "DrugBank::DB12917",
      "drug_name": "DB12917",
      "score": 0.9736781120300293,
      "mechanism_story": "The primary mechanistic link between DB12917 and MONDO:0015175 involves the gene *IL3* (3605), which activates the *R-HSA-4086398* (TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway), ultimately contributing to MONDO:0015175. Alternatively, *IL3* may also influence MONDO:0015175 through a secondary pathway involving *IFNG* (3458) and *TNF* (7124), which further modulate inflammatory or immune responses. An additional connection involves *IL3* interacting with *HOXA9* (3162) to regulate the *R-HSA-4086398* pathway, reinforcing the role of non-canonical NF-kB signaling in the disease mechanism. These pathways highlight *IL3* as a central mediator, with downstream effects driven by *IFNG*, *TNF*, *HOXA9*, and the *R-HSA-4086398* pathway.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 87
    },
    {
      "drug_id": "DrugBank::DB00005",
      "drug_name": "DB00005",
      "score": 0.9733483195304871,
      "mechanism_story": "The primary mechanistic link between DB00005 and MONDO:0015175 involves DB00005 acting through its interaction with DB00563, which targets the gene NGF (4790). This interaction activates the NF-kappaB signaling pathway (R-HSA-4086398), ultimately contributing to the phenotypic manifestations of MONDO:0015175. Alternatively, DB00563 may also influence VDR (7422), which regulates CYP24A1 (29126), providing a secondary pathway connecting DB00005 to MONDO:0015175. Both pathways converge through key intermediates—NGF and NF-kappaB in the primary route, and VDR and CYP24A1 in the secondary route—highlighting their roles in the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 88
    },
    {
      "drug_id": "DrugBank::DB01109",
      "drug_name": "DB01109",
      "score": 0.9723185300827026,
      "mechanism_story": "The primary mechanistic link between DB01109 and MONDO:0015175 involves the gene *PEPD* (5196), which interacts with *IL7R* (3576) to influence the disease phenotype. This connection is supported by two distinct paths of equal weight, both highlighting *PEPD* and *IL7R* as central intermediates. Alternatively, *PEPD* may also modulate MONDO:0015175 through *APOA1* (3481) and *TNF* (7124), forming a secondary pathway. Additionally, another secondary route involves *PEPD* interacting with *KLK3* (3827) before converging on *IL7R*. Together, these pathways suggest that DB01109's effects on MONDO:0015175 are mediated primarily through *PEPD*, with downstream involvement of *IL7R*, *APOA1*, *TNF*, and *KLK3* as key intermediates.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 89
    },
    {
      "drug_id": "DrugBank::DB05332",
      "drug_name": "DB05332",
      "score": 0.971312940120697,
      "mechanism_story": "The primary mechanistic link between DB05332 and MONDO:0015175 involves the inhibition of FGR (2217), which subsequently reduces the activation of IFNG (3458), leading to downstream modulation of TNF (7124) and ultimately affecting MONDO:0015175. An alternative pathway also begins with DB05332 inhibiting FGR (2217), but instead impacts the AR (213) gene, which then influences IL2 (3576) before converging on MONDO:0015175. Both pathways highlight FGR (2217) as a central intermediary, with the primary route involving IFNG (3458) and TNF (7124), while the secondary route involves AR (213) and IL2 (3576). These connections suggest that DB05332 may influence MONDO:0015175 through distinct but interconnected inflammatory and hormonal signaling pathways.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 90
    },
    {
      "drug_id": "DrugBank::DB00091",
      "drug_name": "DB00091",
      "score": 0.9691576361656189,
      "mechanism_story": "The primary mechanistic link between DB00091 and MONDO:0015175 involves DB00091 targeting **AHCY (10105)**, which interacts with **TNF (7124)** to influence MONDO:0015175. AHCY's role in methylation pathways may modulate TNF-mediated inflammatory or immune responses, contributing to the disease phenotype. Alternatively, a secondary pathway connects DB00091 to MONDO:0015175 through AHCY's interaction with **BCL2 (596)**, which is part of the **R-HSA-4086398 (FOXO-mediated transcription) pathway**. This suggests that DB00091 may also affect MONDO:0015175 by regulating BCL2-dependent apoptotic or survival signals via FOXO-mediated transcriptional control. Both pathways highlight AHCY as a central intermediary, with TNF and BCL2/FOXO signaling as key downstream effectors.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 91
    },
    {
      "drug_id": "DrugBank::DB00207",
      "drug_name": "DB00207",
      "score": 0.9679148197174072,
      "mechanism_story": "The primary mechanism linking DB00207 to MONDO:0015175 involves the inhibition of the *IFNG* gene (Entrez ID: 3458) via the intermediate *CD14* (Entrez ID: 939), ultimately affecting the disease phenotype. DB00207 first interacts with *CD14*, which then modulates *IFNG* expression, a key cytokine implicated in immune regulation. Two alternative pathways further elaborate this connection: one where *IFNG* influences *TNF* (Entrez ID: 7124), another critical immune-related gene, and another where *IFNG* participates in the \"IFN-gamma signaling\" pathway (R-HSA-4086398), both converging on MONDO:0015175. These interactions highlight the central role of *CD14* and *IFNG* in mediating the link between DB00207 and the disease, with secondary contributions from *TNF* and IFN-gamma signaling.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 92
    },
    {
      "drug_id": "DrugBank::DB14996",
      "drug_name": "DB14996",
      "score": 0.9656938910484314,
      "mechanism_story": "The primary mechanistic link between DB14996 and MONDO:0015175 involves the gene *FYN* (716), which connects through *FYN*'s interaction with *IL2RB* (3576), a key component in immune signaling pathways. Alternatively, *FYN* also links to MONDO:0015175 via *CD247* (2247) and *CD3E* (7124), both of which are critical for T-cell receptor signaling. These pathways suggest that DB14996 may influence MONDO:0015175 through *FYN*-mediated modulation of immune-related processes, either via *IL2RB* or the *CD247-CD3E* axis, both of which converge on the disease phenotype.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 93
    },
    {
      "drug_id": "DrugBank::DB00981",
      "drug_name": "DB00981",
      "score": 0.9650255441665649,
      "mechanism_story": "The primary mechanistic link between DB00981 and MONDO:0015175 involves MAPK1 (gene 5599) and the ERK/MAPK signaling pathway (R-HSA-4086398), where DB00981 acts through the intermediate gene MAPK14 (gene 1436) to modulate this pathway, ultimately influencing MONDO:0015175. Alternatively, DB00981 may also affect MONDO:0015175 through MAPK14 (gene 1436) and the gene IL7R (gene 3575), highlighting a secondary pathway involving interleukin-7 receptor signaling. Both pathways converge on MONDO:0015175, with MAPK14 serving as a central intermediate in connecting DB00981 to the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 94
    },
    {
      "drug_id": "DrugBank::DB09086",
      "drug_name": "DB09086",
      "score": 0.964396595954895,
      "mechanism_story": "The primary mechanism linking DB09086 to MONDO:0015175 involves the inhibition of NFKB1 (4790), which suppresses the NF-kappa B signaling pathway (R-HSA-4086398), thereby contributing to the disease phenotype. Alternatively, NFKB1 inhibition may also downregulate IFNG (3439), a key cytokine implicated in immune regulation and disease pathogenesis. Secondary pathways include NFKB1-mediated suppression of SPP1 (6696), which reduces the expression of TNFRSF11A (7124), a receptor involved in osteoclast activation, or NFKB1's indirect effect on APOBEC3G (9370), leading to altered IL2 (3576) signaling, both of which may further modulate disease progression. These interconnected pathways highlight NFKB1 as a central regulator bridging DB09086's action to MONDO:0015175.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 95
    },
    {
      "drug_id": "DrugBank::DB00910",
      "drug_name": "DB00910",
      "score": 0.9578681588172913,
      "mechanism_story": "The primary mechanism linking DB00910 to MONDO:0015175 involves the NFKB1 gene (4790) and the \"Ca2+ pathway\" (R-HSA-4086398), suggesting that DB00910 may influence MONDO:0015175 through NFKB1-mediated calcium signaling. Alternatively, DB00910 may act via the IL6 gene (3606) and IFNG (3439), implicating interleukin-6 and interferon-gamma as key intermediates in an inflammatory pathway. Secondary paths further highlight NFKB1's role, connecting it through SPP1 (6696) and BCL2 (7124), which may involve osteopontin and apoptosis regulation. Similarly, IL6 links to MONDO:0015175 via ADAM17 (9370) and TNF (3576), indicating a potential TNF-alpha-dependent inflammatory cascade. Together, these pathways suggest DB00910's effects on MONDO:0015175 may involve NFKB1-driven calcium signaling, IL6/IFNG-mediated inflammation, and TNF-alpha-related mechanisms.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 96
    },
    {
      "drug_id": "DrugBank::DB00437",
      "drug_name": "DB00437",
      "score": 0.9507566690444946,
      "mechanism_story": "The primary mechanism linking DB00437 to MONDO:0015175 involves the direct activation of the pathway R-HSA-4086398 (weight: 20.00). Alternatively, DB00437 may indirectly influence MONDO:0015175 through two secondary pathways. In the first alternative (weight: 30.00), DB00437 targets the gene NFE2L2 (4780), which upregulates HMOX1 (3162), subsequently activating R-HSA-4086398. In the second alternative (weight: 36.00), DB00437 also acts on NFE2L2 (4780), which then modulates SPP1 (6696) and BGLAP (7124), ultimately leading to MONDO:0015175. These pathways highlight the central role of NFE2L2 and R-HSA-4086398 in connecting DB00437 to the disease phenotype.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 97
    },
    {
      "drug_id": "DrugBank::DB09274",
      "drug_name": "DB09274",
      "score": 0.9500919580459595,
      "mechanism_story": "The primary mechanism linking DB09274 to MONDO:0015175 involves the gene **HSP90AA1 (3162)**, which activates the **NF-κB signaling pathway (R-HSA-4086398)**, directly contributing to the disease phenotype. Alternatively, DB09274 may influence MONDO:0015175 through two secondary pathways: one involving the gene **NFE2L2 (4780)**, which upregulates **SPP1 (6696)**, leading to **BTRC (7124)** and subsequently the disease; or another where **HSP90AA1 (3162)** modulates **BTRC (7124)** via **PRKDC (6648)**, ultimately connecting to MONDO:0015175. These pathways highlight the central roles of **HSP90AA1**, **NF-κB signaling**, **NFE2L2**, **SPP1**, and **BTRC** in mediating the relationship between DB09274 and the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 98
    },
    {
      "drug_id": "DrugBank::DB00398",
      "drug_name": "DB00398",
      "score": 0.9469144344329834,
      "mechanism_story": "The primary mechanistic link between DB00398 (a drug) and MONDO:0015175 (a disease) involves the drug's interaction with the STAT4 gene (6775), which subsequently activates the \"Ca2+ pathway\" (R-HSA-4086398), ultimately contributing to the disease phenotype. An alternative pathway also originates with STAT4 but diverges through its interaction with the IFNG gene (3458), which then influences the TNF gene (7124) before linking to the disease. Additionally, STAT4 may alternatively engage the PIK3CA gene (5290), which converges back onto the Ca2+ pathway (R-HSA-4086398) to mediate the disease connection. Thus, STAT4 serves as the central hub, with downstream effects either directly through the Ca2+ pathway or indirectly via IFNG/TNF or PIK3CA-mediated signaling.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 99
    },
    {
      "drug_id": "DrugBank::DB02513",
      "drug_name": "DB02513",
      "score": 0.9457941651344299,
      "mechanism_story": "The primary mechanistic link between DB02513 and MONDO:0015175 involves the inhibition of NFKB1 (4790), which suppresses the NF-κB signaling pathway (R-HSA-4086398), thereby potentially influencing the disease phenotype. Alternatively, DB02513 may also act through NFKB1 to downregulate IFNG (3439), a cytokine implicated in immune regulation, offering another route to MONDO:0015175. Secondary pathways include NFKB1-mediated suppression of SPP1 (6696), which reduces the expression of TGFB1 (7124), or inhibition of ADAM17 (9370), leading to decreased IL6R (3576) activity. These interconnected pathways highlight NFKB1 as a central regulator, with downstream effects on immune and inflammatory mediators (IFNG, SPP1/TGFB1, ADAM17/IL6R) contributing to the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 100
    },
    {
      "drug_id": "DrugBank::DB09301",
      "drug_name": "DB09301",
      "score": 0.9364844560623169,
      "mechanism_story": "The primary mechanistic link between DB09301 and MONDO:0015175 involves DB09301 acting through its metabolite DB08895, which modulates the Reactome pathway R-HSA-4086398, ultimately influencing the disease phenotype (Weight: 30.00). Alternatively, DB08895 may also exert effects via the gene FGF2 (2247), which interacts with TNF (7124) to contribute to the disease. A parallel pathway involves DB08895 impacting VEGFA (7422), which then interacts with S100A8 (29126) to mediate the connection to MONDO:0015175 (both Weight: 38.00). These pathways highlight the central roles of DB08895, R-HSA-4086398, FGF2, TNF, VEGFA, and S100A8 in bridging the relationship between the drug and the disease.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 101
    },
    {
      "drug_id": "DrugBank::DB00242",
      "drug_name": "DB00242",
      "score": 0.9364731311798096,
      "mechanism_story": "The primary mechanism linking DB00242 to MONDO:0015175 involves IL13 (10461) and the IL-13 signaling pathway (R-HSA-4086398), suggesting that DB00242 may influence MONDO:0015175 through IL-13-mediated signaling. Alternatively, DB00242 may act via IL10 (3586), which connects to MONDO:0015175 through either IFNG (3439) or through a longer pathway involving SPP1 (6696) and TGFB1 (7124). A third potential route involves IL10 (3586) interacting with LTA (3952) and IL5 (3576), further implicating cytokine-mediated pathways in the association between DB00242 and MONDO:0015175. These connections highlight the central roles of IL13, IL10, IFNG, SPP1, TGFB1, LTA, and IL5 as key intermediates in the potential mechanistic links.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 102
    },
    {
      "drug_id": "DrugBank::DB01039",
      "drug_name": "DB01039",
      "score": 0.9238387942314148,
      "mechanism_story": "The primary mechanism linking DB01039 (a drug) to MONDO:0015175 (a disease) involves the drug's interaction with PPARA (5465), which subsequently modulates IL7R (3576), directly connecting to the disease. An alternative pathway also originates with PPARA (5465) but instead activates RELA (5970), leading to the NF-kappa B signaling pathway (R-HSA-4086398) before associating with the disease. Additionally, a third pathway involves PPARA (5465) upregulating SPP1 (6696), which then influences TNF (7124) as an intermediate step prior to disease linkage. Together, these pathways highlight PPARA as a central hub, with downstream effects on immune-related genes (IL7R, RELA, TNF) and the NF-kappa B pathway as key intermediates in the drug-disease relationship.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 103
    },
    {
      "drug_id": "DrugBank::DB01593",
      "drug_name": "DB01593",
      "score": 0.9143630266189575,
      "mechanism_story": "The primary mechanism linking DB01593 to MONDO:0015175 is a direct connection (weight: 10.00). Alternatively, DB01593 may influence MONDO:0015175 through secondary pathways involving key intermediates. One pathway (weight: 28.00) involves the gene 30009, which activates the Reactome pathway R-HSA-4086398, ultimately leading to MONDO:0015175. Another pathway (weight: 28.00) proceeds through the gene 50943, which interacts with 29126 to affect the disease. Two longer pathways (weight: 36.00 each) involve distinct cascades: one via the genes 2744, 3315, and 7124, and another through 50943, 1437, and 3439, both converging on MONDO:0015175. These connections highlight the roles of genes like 30009, 50943, and 2744, as well as pathways such as R-HSA-4086398, in mediating the relationship between DB01593 and MONDO:0015175.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 104
    },
    {
      "drug_id": "DrugBank::DB09287",
      "drug_name": "DB09287",
      "score": 0.8977926969528198,
      "mechanism_story": "The primary mechanistic link between DB09287 (a drug) and MONDO:0015175 (a disease) involves DB09287 acting through its metabolite DB00563, which targets the NFKB1 gene (4790). NFKB1 is a key regulator of the NF-kappa B signaling pathway (R-HSA-4086398), a central pathway implicated in the pathogenesis of MONDO:0015175. Alternatively, DB00563 may also interact with the VDR gene (7422), which modulates the expression of CYP24A1 (29126), another gene associated with the disease. Both pathways converge on MONDO:0015175, with NFKB1 and VDR serving as critical intermediate genes linking the drug's metabolite to the disease mechanism.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 105
    },
    {
      "drug_id": "DrugBank::DB09053",
      "drug_name": "DB09053",
      "score": 0.8827530741691589,
      "mechanism_story": "The primary mechanistic link between DB09053 and MONDO:0015175 involves the intermediate gene **TNF (695)**, which connects to **TNFRSF1A (7132)** and subsequently to MONDO:0015175, suggesting a TNF-mediated inflammatory pathway. Alternatively, DB09053 also acts through **TNF (695)** but diverges via **TGFB1 (7040)**, implicating TGF-β signaling through **IL6 (3569)** before reaching MONDO:0015175. Both pathways highlight the central role of **TNF (695)** in mediating these connections, with secondary involvement of **TNFRSF1A (7132)** or **TGFB1 (7040)** and **IL6 (3569)** as key intermediates in the inflammatory or immune-regulatory pathways leading to MONDO:0015175.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 106
    },
    {
      "drug_id": "DrugBank::DB00703",
      "drug_name": "DB00703",
      "score": 0.8649299740791321,
      "mechanism_story": "The primary mechanistic link between DB00703 and MONDO:0015175 involves the gene **AXIN1 (8312)**, which interacts with **CTNNB1 (1499)** to regulate the **IL6 (3576)** signaling pathway, ultimately connecting to MONDO:0015175. An alternative pathway also originates with AXIN1 but instead engages **TP53 (7157)** and **S100A4 (29126)**, suggesting a secondary route involving p53-mediated signaling and S100A4's role in cellular processes. Both pathways converge on MONDO:0015175, highlighting AXIN1 as a central intermediate that bridges Wnt/β-catenin (via CTNNB1) and p53-dependent mechanisms.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 107
    },
    {
      "drug_id": "DrugBank::DB00783",
      "drug_name": "DB00783",
      "score": 0.8099353909492493,
      "mechanism_story": "The primary mechanism linking DB00783 to MONDO:0015175 involves the gene IL8 (3576), which directly connects to MONDO:0015175 through the NF-kappa B signaling pathway (R-HSA-4086398). Alternatively, IL8 may also influence MONDO:0015175 via its interaction with the IFNG gene (3439). A secondary pathway involves IL8 upregulating its own expression through the transcription factor NFKB1 (5196), creating a feedback loop that further contributes to the disease. Additionally, IL8 may indirectly affect MONDO:0015175 through the BCL2 gene (6648) and its interaction with the apoptosis regulator BCL2L1 (7124), suggesting a role in cell survival pathways. These connections highlight IL8 as a central mediator, with NF-kappa B signaling, IFNG, NFKB1, and BCL2/BCL2L1 as key intermediates.",
      "matched_cluster_id": 1,
      "matched_cluster_theme": "NF-κB signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 108
    },
    {
      "drug_id": "DrugBank::DB00995",
      "drug_name": "DB00995",
      "score": 0.6851308941841125,
      "mechanism_story": "The primary mechanistic link between DB00995 and MONDO:0015175 involves the gene NFKB1 (4780), which connects through the NF-κB signaling pathway (R-HSA-4086398), suggesting modulation of inflammatory or immune responses as a key intermediate step. Alternatively, DB00995 may act via the gene TNFRSF1A (4790), which interacts with IFNG (3439), implicating cytokine signaling in the pathway. Two secondary paths further elaborate these connections: NFKB1 (4780) can also influence MONDO:0015175 through SPP1 (6696) and TGFB1 (7124), highlighting roles in extracellular matrix regulation and fibrotic processes, while TNFRSF1A (4790) may act via ADAM17 (9370) and IL6 (3576), indicating involvement in cytokine release and inflammatory cascades. Together, these pathways converge on MONDO:0015175 through NF-κB, cytokine signaling, and fibrotic or inflammatory mediators.",
      "matched_cluster_id": 0,
      "matched_cluster_theme": "NF-kappa B signaling pathway",
      "is_true_positive": false,
      "cross_disease_score": 0.0,
      "rank": 109
    }
  ]
}